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INTRODUCTION  
 
                          The advent of plasmid mediated ESBL production by Klebsiella and E. 
coli in the early 1980s signaled an emerging and evolving global problem with antibiotic 
resistance among Enterobacteriaceae. These organisms were susceptible to β-lactam 
antibiotics, but, with widespread use, have developed resistance through production of β-
lactamases,  which are the major defense mechanism of gram-negative bacteria against β-
lactam antibiotics, and were first reported in the early 1980s.1 
                        The presence of ESBLs carries tremendous clinical significance. Plasmids 
responsible for ESBL production frequently carry genes encoding resistance to other drug 
classes (for example, aminoglycosides), thus limiting the antibiotic options available for 
treatment of resistant strains .2 Thus, it becomes imperative to quantify the problem, and 
reinforce guidelines promoting appropriate antibiotic use. 
                        Since -lactam antibiotics came into clinical use, -lactamases have 
coevolved with them. As and when agents like cephamycins, cephalosporins with an 
oxyimino side chain, carbapenems, and aztreonam, that could break through the 
antimicrobial resistance were introduced,  bacteria responded with a plethora of "new" -
lactamases —including extended-spectrum -lactamases (ESBLs), plasmid-mediated 
AmpC enzymes, and carbapenem-hydrolyzing -lactamases (carbapenemases) — that, 
with variable success, can confer resistance to the latest -lactam antibiotics.3 Presumably 
the selective pressure by the use and overuse of these new introductions periodically for 
the treatment of patients, has allowed the proliferation and survival of new variants of     
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β-lactamase. Thus, ESBLs represent an impressive example of the ability of gram-
negative bacteria to develop new antibiotic resistance mechanisms in the face of the 
introduction of new antimicrobial agents.  
                         Antimicrobial resistance development is a function of bacterial genetic 
variability, such as the replication or generation rate in response to environmental stress 
(physical, nutrient availability etc), and selection pressure due to the use of similar 
antibiotics (class).  The spreading antimicrobial resistance may be due to dispersion of 
resistant clones, or the genomes rapidly expanding its reservoirs or massive consumption 
of antimicrobials due to worldwide usage. 
                        The prevalence of ESBL production among gram-negative bacilli varies 
widely and has been found to range from 3.3% to 86.6%, depending upon the clinical 
setting and the geographic region43In a study done in a tertiary care centre in India, ESBL 
was detected in in 80% of Klebsiella spp. and 68% among all gram negative bactria.4 
Risk factors for the occurrence of ESBL producing organisms have been studied in 
various settings and include  an increased length of stay in the hospital, an increased 
length of stay in the intensive care unit, increased severity of illness emergency 
abdominal surgery, prior administration of an oxyimino- -lactam antibiotic,  and prior 
administration of any antibiotic.5-8 
                                          It must be admitted there are few national policies or guidelines 
governing rational antibiotic use. This study looks at the magnitude of this problem in a 
tertiary care setting and the role of antibiotic administration, in promoting the  
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development of resistant strains, and in being appropriate or otherwise, for containing 
such strains. 
                     Previous studies have shown a significant effect of ESBL production on 
mortality. However, there are no prospective studies to evaluate the risk factors for 
mortality among patients with severe infections due to ESBL producing strains of E. coli 
and Klebsiella. This study was mainly done to assess the risk factors for ESBL 
production, antibiotic details and appropriateness and outcome in patients with the above 
infections.  
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                     OBJECTIVES OF THE STUDY 
 
      To determine 
1. The prevalence of ESBL producing isolates of E.coli and Klebsiella among 
bacteremic adult hospitalized patients, 
2. The rates of ESBL production among community acquired and nosocomial 
infections, 
3. The risk factors for bacteremia due to ESBL producing E. coli and Klebsiella 
species. 
4. The outcome of antibiotic treatment in bacteremia caused by E. coli and 
Klebsiella species in hospitalized adults. 
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Figure 1. Structure of  β-lactam antibiotics 
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                       REVIEW OF LITERATURE 
 
             
Overview of the β-lactam antibiotics 
                           β-lactam antibiotics are among the most commonly prescribed drugs; 
they are grouped together based upon a shared structural feature, the β - lactam ring. β -
lactam antibiotics include: Penicillins, Cephalosporins, Cephamycins, Carbapenems and  
Monobactams.9 The basic structure of these antibiotics is shown in figure 1. "R" 
represents sites where different chemical side chains attach, depending on the particular 
antibiotic. 
 
Mechanism of action9 
                          β-lactam antibiotics inhibit the growth of sensitive bacteria by 
inactivating enzymes located in the bacterial cell membrane, which are involved in the 
third stage of cell wall synthesis. It is during this stage that linear strands of 
peptidoglycan are cross-linked into a fishnet-like polymer that surrounds the bacterial cell 
and confers osmotic stability in the hypertonic milieu of the infected patient. β-lactams 
inhibit not just a single enzyme involved in cell wall synthesis, but a family of related 
enzymes (four to eight in different bacteria), each involved in different aspects of cell 
wall synthesis. These enzymes can be detected by their covalent binding of radioactively-
labeled penicillin (or other β-lactams) and hence have been called penicillin binding 
proteins (PBPs).2 Different penicillin binding proteins appear to serve different functions  
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for the bacterial cell. As an example, PBP2 in Escherichia coli is important in 
maintaining the rod-like shape of the bacillus, while PBP3 is involved in septation during  
cell division.10  Different β-lactam antibiotics may preferentially bind to and inhibit 
certain PBPs more than others. Thus, different agents may produce characteristic effects 
on bacterial morphology and have different efficacies in inhibiting bacterial growth or 
killing the organism.  
                       β-lactam antibiotics are generally bactericidal against organisms that they 
inhibit. The mechanism of bacterial cell killing is an indirect consequence of the 
inhibition of bacterial cell wall synthesis. Enzymes that mediate autolysis of 
peptidoglycan are normally present in the bacterial cell wall but are strictly regulated to 
allow breakdown of the peptidoglycan only at growing points. β-lactam inhibition of cell 
wall synthesis leads to activation of the autolytic system through a two component 
system, VncR/S, which initiates a cell death program.11 Certain bacteria are deficient in 
these autolytic enzymes or have mutations in the regulatory genes; these strains show the 
phenomenon of "tolerance" to β-lactam antibiotics, that is, their growth is inhibited by the 
antibiotic but the bacteria are not killed. 
 
Mechanisms of bacterial resistance12,13 
                     Three general mechanisms of bacterial resistance to antibiotics, including 
the β-lactams, have been well characterized: decreased penetration to the target site; 
alteration of the target site; and inactivation of the antibiotic by a bacterial enzyme.  
Decreased penetration to the target site: The outer membrane of Gram negative bacilli 
provides an efficient barrier to the penetration of beta-lactam antibiotics to their target  
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Figure 2. Mechanism of action of  β-lactamases. 
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1. PBPs in the bacterial plasma membrane. β-lactams usually must pass through the 
hydrophilic porin protein channels in the outer membrane of Gram negative bacilli to  
      reach the periplasmic space and plasma membrane. The permeability barrier of the 
outer membrane is a major factor in the resistance of Pseudomonas aeruginosa to 
many β-lactam antibiotics.  
2. Alteration of the target site: The target sites for the β-lactams are the PBPs in the 
cytoplasmic membrane. Alterations in PBPs may influence their binding affinity for 
beta-lactam antibiotics and therefore the sensitivity of the altered bacterial cell to 
inhibition by these antibiotics. Such a mechanism is responsible for penicillin 
resistance in pneumococci14, methicillin (oxacillin) resistance in staphylococci15, and 
for bacteria with increasing intrinsic resistance to β-lactams, such as gonococci, 
enterococci, and Haemophilus influenzae.  
3. Inactivation by a bacterial enzyme: Production of β-lactamase is the major 
mechanism of resistance to the β-lactam antibiotics in clinical isolates. Such bacterial 
enzymes may cleave predominantly penicillins (penicillinases), cephalosporins 
(cephalosporinases), or both (β-lactamases), shown in figure 2. Their production may 
be encoded within the bacterial chromosome (and hence be characteristic of an entire 
species) or the genes may be acquired on a plasmid or transposon (and hence be 
characteristic of an individual strain rather than the species). Bacteria may synthesize 
the β-lactamase constitutively (as for many plasmid-mediated enzymes) or synthesis 
may be inducible in the presence of antibiotic (as for many chromosomal enzymes). 
Inducible β-lactamases may not be reliably detected by initial susceptibility testing, 
particularly with the newer rapid methods. 
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Table 1. Key dates of evolution of ESBL 
 
Source: Chaudary et al. ESBL. An emerging threat to clinical therapeutics. IJMR 2004;22(2): 75 – 80. 
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Evolution and Dissemination of β-Lactamases 9 
                           Fifty years ago, the antibiotic era began with the discovery of penicillin. 
With in a few years of introduction of penicillin into clinical use, penicillinase producing 
Staphylococcus aureus started to proliferate in hospitals. To overcome this problem, 
penicillinase resistant penicillins came into picture. Shortly afterward, the broad spectrum 
penicillins and first generation cephalosporins were introduced. They remained a first line 
of defense against microbes for over 20 years, before resistance due to β-lactamases 
produced by gram negative bacilli became a serious problem.2 To counter this threat, the 
pharmaceutical industry marketed six novel classes of β-lactam antibiotics (cephamycins, 
oxyimino cephalosporins, carbapenems, monobactams and clavam and penicillianic acid 
sulfone inhibitors) within a relatively short span of 7-8 years. Although, novel β-
lactamases had emerged gradually after the introduction of new β- lactam agents, their 
number and variety accelerated at an alarming rate.16 More than 170 β-lactamases have 
been recognized at present.  
                       ESBLs are most likely to be found in K. pneumoniae, K. oxytoca, and E. 
coli but have been reported in Citrobacter, Enterobacter, Proteus, Salmonella, Serratia, 
and other genera of enteric organisms17 and in such nonenteric organisms as 
Acinetobacter baumannii 18,19 and P. aeruginosa.20 
 
The evolution of these enzymes over the years is shown in Table1. 
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Table 2. The Bush  Jacoby Medeiros  classification 
 
 
 
Source: Chaudary et al. ESBL. An emerging threat to clinical therapeutics. IJMR 2004;22(2): 75 – 80. 
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Classification of   Extended spectrum β-lactamases 
                    Various classification schemes have been proposed by many researchers.21 
Classification of Sawai et al,22 in 1968 was based on response to antisera and  the  
Richmond and Sykes scheme in 1973 was on the basis of substrate profile. Extension of 
the Richmond and Sykes scheme by Sykes and Mathew in 1976, was based on 
differentiation by isoelectric focussing.23) In the scheme proposed by Mitsuhashi and 
Inoue in 1981,24 the category “cefuroxime hydrolyzing β-lactamases” was added to 
“penicillinase and cephalosporinase” classification. The groupings proposed by Bush in 
1989 was based on correlation of substrate and inhibitory properties with molecular 
structure.21  However, the number and variety of enzymes have proliferated beyond the 
boundaries of the scheme. A more modern scheme based on molecular structure 
classification was proposed by Ambler,25  includes only those enzymes that have been 
characterized. Recently a new classification scheme has been developed to integrate 
functional and molecular characteristics. The Bush-Jacoby-Medeiros scheme2 classifies a 
total of 178 β-lactamases from naturally occurring bacterial isolates into four groups 
based on substrate and inhibitor profiles, this is shown in table 2. The enzymes can be 
classified on the basis of their primary structure into four molecular classes (A through 
D),25 or on the basis of their substrate spectrum and responses to inhibitors into a larger 
number of functional groups. Class A and class C β-lactamases are the most common and 
have a serine residue at the active site, as do class D β-lactamases. Class B comprises the 
metallo-β-lactamases.  
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Important ESBL s : 
 
TEM-Type ESBLs (Class A) : 
Amino acid substitutions at many sites in TEM-1 β-lactamases can be created in the 
laboratory without loss of activity.26 Those responsible for the ESBL phenotype change 
the configuration of the active site of the enzyme, allowing access to oxyimino-β-
lactams.27,28 Opening the active site to β-lactam substrates also typically enhances the 
susceptibility of the enzyme to β-lactamase inhibitors, such as clavulanic acid. Amino 
acid substitutions distinct from those leading to the ESBL phenotype can confer 
resistance to inhibitors, but the combination of inhibitor resistance and an extended 
spectrum of activity seems to be, with rare exceptions incompatible.29 More than 130 
TEM enzymes are currently recognized, and their variety provides a useful way to follow 
the spread of individual resistance genes. TEM-10, TEM-12, and TEM-26 are among the 
most common in North and South America.7 
SHV-Type ESBLs (Class A) : 
SHV-1 shares 68 percent of its amino acids with TEM-1 and has a similar overall 
structure.30 As with TEM, SHV-type ESBLs have one or more amino acid substitutions 
around the active site. More than 50 varieties of SHV are currently recognized on the 
basis of unique combinations of amino acid replacements. SHV-type ESBLs currently 
predominate in surveys of resistant clinical isolates in Europe and America. 7,31 SHV-5 
and SHV-12 are among the most common members of this family. 
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CTX-M–Type ESBLs (Class A) : 
The most common group of ESBLs not belonging to the TEM or SHV families was 
termed CTX-M to highlight their greater activity against cefotaxime than against 
ceftazidime. More than 40 CTX-M enzymes are currently known. Belying their name, 
some hydrolyze ceftazidime more rapidly than they do cefotaxime. CTX-M-14, CTX-M-
3, and CTX-M-2 are the most widespread of these. 
Other Class A ESBLs:  
Other Class A ESBLs are uncommon and have been found mainly in Pseudomonas 
aeruginosa and at a limited number of geographic sites: PER-1 in isolates in Turkey, 
France, and Italy; VEB-1 and VEB-2 in strains from Southeast Asia; and GES-1, GES-2, 
and IBC-2 in isolates from South Africa, France, and Greece. 20  PER-1 is also common 
in multi resistant Acinetobacter species in Korea and Turkey. 32 Some of these enzymes 
are found in Enterobacteriaceae as well, whereas other uncommon ESBLs (such as BES-
1, IBC-1, SFO-1, and TLA-1) have been found only in Enterobacteriaceae.33 
OXA-Type ESBLs (Class D) : 
Twelve ESBLs derived from OXA-10, OXA-1, or OXA-2 by amino acid substitutions are 
currently known.34 They have been found mainly in P. aeruginosa in specimens from 
Turkey and France. Most OXA-type ESBLs are relatively resistant to inhibition by 
clavulanic acid. Some confer resistance predominantly to ceftazidime, but OXA-17 
confers greater resistance to cefotaxime and cefepime than it does resistance to 
ceftazidime.35 
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Plasmid-Mediated AmpC Enzymes (Class C) : 
AmpC -lactamases, usually inducible by -lactams, are encoded by chromosomal genes 
in many gram-negative bacilli. Mutations that increase their expression are responsible 
for the ready emergence of broad-spectrum cephalosporin resistance in Enterobacter 
cloacae. 36 The AmpC enzyme in E. coli is poorly expressed and the AmpC gene is 
missing from the chromosome of Klebsiella and Salmonella species, but plasmid-
mediated AmpC enzymes can give these organisms the same resistance profile as a -
lactam–resistant enterobacter isolate. More than 20 different AmpC -lactamases have 
been found to be mediated by plasmids. Some, like the parental chromosomal enzymes, 
are accompanied by regulatory genes and are inducible, but most are not. 
Characteristically, AmpC -lactamases provide resistance to cephamycins as well as to 
oxyimino- -lactams and are resistant to inhibition by clavulanic acid. 
 
Carbapenemases (Classes A, B, and D) : 
Carbapenemases are a diverse group of enzymes. They are currently uncommon but are a 
source of considerable concern because they are active not only against oxyimino-
cephalosporins and cephamycins but also against carbapenems 37.Plasmid-mediated IMP-
type carbapenemases, 17 varieties of which are currently known, became established in 
Japan in the 1990s in both enteric gram-negative organisms and in pseudomonas and 
acinetobacter species. IMP enzymes spread slowly to other countries in the Far East, 
were reported from Europe in 1997, and have been found in Canada and Brazil. A second  
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                           Figure 3. Genetics of  β-lactamases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IR denotes inverted repeat, bla -lactamase gene, dfr dihydrofolate reductase gene, qac 
gene conferring resistance to quaternary ammonium compounds, delta deletion 
derivative, intI site-specific integrase gene, aad aminoglycoside adenylyltransferase 
gene, sul dihydropteroate synthetase gene, ORF open-reading frame, attI 
recombination site, 59be 59-base element, aac aminoglycoside acetyltransferase gene, 
and IS insertion sequence. 
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growing family of carbapenemases, the VIM family, was reported from Italy in 1999 and 
now includes 10 members, which have a wide geographic distribution in Europe, South  
America, and the Far East and have been found in the United States . A few class A 
enzymes, notably the plasmid-mediated KPC enzymes, are effective carbapenemases as 
well. Finally, some OXA-type β-lactamases have carbapenemase activity, augmented in 
clinical isolates by additional resistance mechanisms, such as impermeability or efflux. 
 
 
 
Genetics of β-Lactamases 
                        Plasmids are responsible for the spread of most of the new β-lactamases, 
but the genes encoding these enzymes may also be located on the bacterial chromosome. 
The genes encoding some β-lactamases are carried by transposons.. Genes for many of 
the new β-lactamases are found in integrons, which often include genes conferring 
resistance to other antibiotics. For this reason, the new β-lactamases are usually produced 
by organisms that are resistant to multiple antimicrobial agents. Occasionally, the ESBL 
phenotype emerges in an organism isolated from a patient treated for multiple episodes of 
bacteremia, but much more often an ESBL-producing plasmid or strain disseminates to 
multiple patients, so that in hospital outbreaks one type of ESBL often predominates. 
Particular TEM-type ESBL varieties seem to have a fixed geographic distribution, 
whereas at least some SHV types have been found all over the world, suggesting that they 
have a multifocal origin. For example, TEM-3 is common in France and has been 
reported in a few other European countries but has not been reported in the United States, 
whereas SHV-5 and SHV-12 have been detected worldwide. The genes encoding the 
TEM-1 and TEM-2 β-lactamases are carried by transposons, as are the genes encoding  
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some TEM-type ESBLs .The gene encoding SHV-1 is found on the chromosome of most 
strains of K. pneumoniae. SHV genes also occur on transmissible plasmids; for example,  
one has been found on a 7.5-kb block of DNA apparently captured from the Klebsiella 
chromosome. Genes encoding the remaining types of β-lactamase are often found 
incorporated into integrons but have their origin elsewhere. For example, the genes for 
CTX-M–type enzymes are found on the chromosome of Kluyvera, a genus of rarely 
pathogenic commensal organisms. Rather than evolving from a progenitor with a more 
limited spectrum of activity, the CTX-M group appears to have emerged in multiple 
places by plasmid acquisition of β-lactamase genes from such a widespread 
environmental reservoir. The genetic units encoding various β-lactamases are 
schematically depicted in figure 3. Diagrams of transposons and integrons encoding 
TEM-1, CTX-M-9, and VIM-2   -lactamases are shown. Integrons are also involved in the 
acquisition of AmpC-type β-lactamases by plasmids. Many of these plasmid-mediated 
enzymes can be related to chromosomal mpC enzymes of particular species: thus, ACC-1 
is related to the enzyme produced by Hafnia alvei; ACT-1 and MIR-1 to enzymes of 
enterobacter species; some CMY enzymes as well as LAT-1 and LAT-3 to enzymes of 
citrobacter species; other CMY enzymes and the FOX and MOX families to enzymes of 
aeromonas species; and DHA-1 to the enzyme of Morganella morganii. Carbapenemases 
of the IMP and VIM families are also found within integrons , but the origin of their 
genes is not yet known. 
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Factors Influencing β-Lactamase Expression: 
                       In addition to the vast number of enzymes, further complications arise 
because expression of resistance is affected by additional factors. The same enzyme may 
express different resistance phenotypes, depending on the bacterial host and the test 
conditions. For ESBLs of the TEM and SHV families, the expanded spectrum is  
accompanied by a loss of intrinsic hydrolytic activity. This loss can be compensated for 
by an increase in gene dosage (through gene duplication or carriage on a multi copy 
plasmid) or the presence of a promoter with increased activity (through a mutation or 
insertion-sequence substitution). In some organisms (Ps. aeruginosa in particular), an 
active efflux system can reduce the intracellular accumulation of antibiotic and allow an 
enzyme with only limited hydrolytic capacity to inactivate the drug before it can reach its 
target; in other organisms, this effect is achieved by diminished expression of an outer-
membrane porin required for -lactam uptake. In Klebsiella pneumoniae, decreased 
expression of outer-membrane porins often accompanies ESBL production and may 
allow a TEM- or SHV-type ESBL to express resistance to cefepime or allow an AmpC -
lactamase to express resistance to Imipenem. 
 
Escherichia coli 38 
 
                           The genus Escherichia is named after Theodor Escherich, who isolated 
the type species of the genus. They are gram-negative bacilli occurring singly or in pairs. 
Escherichia coli is facultatively anaerobic with both a fermentative and respiratory type 
of metabolism. They are either nonmotile or motile by peritrichous flagella. E coli is a 
major facultative inhabitant of the large intestine.  E. coli can generally cause several  
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intestinal and extra-intestinal infections such as urinary tract infections, meningitis, 
peritonitis, mastitis, septicemia and Gram-negative pneumonia. Other miscellaneous 
infections that may be caused by E coli include septic arthritis, endophthalmitis, 
suppurative thyroiditis, sinusitis, osteomyelitis, endocarditis, or skin and soft tissue 
infections (especially in patients who are diabetic). 
                         The enteric E. coli are divided on the basis of virulence properties into  
1. Enterotoxigenic (ETEC, causative agent of diarrhea in humans, pigs, sheep, goats, 
cattle, dogs, and horses),  
2. Enteropathogenic (EPEC, causative agent of diarrhea in humans, rabbits, dogs, cats 
and horses); 
3. Enteroinvasive (EIEC, found only in humans), verotoxigenic (VTEC, found in pigs, 
cattle, dogs and cats); 
4. Enterohaemorrhagic (EHEC, found in humans, cattle, and goats, attacking porcine 
strains that colonize the gut in a manner similar to human EPEC strains) and  
5. Enteroaggregative E. coli (EAggEC, found only in humans).  
                          Isolates from symptomatic infections of the urinary tract, bloodstream, 
cerebrospinal fluid, respiratory tract, and peritoneum (spontaneous bacterial peritonitis) 
are distinct from commensal and intestinal pathogenic strains of E. coli by virtue of their 
functionally similar virulence factor profiles and clonal background. It has recently been 
proposed that these extraintestinal strains of E. coli be termed ExPEC.  Like commensal 
E. coli (but in contrast to intestinal pathogenic E. coli), ExPEC strains are often found in 
the normal intestinal flora and do not cause gastroenteritis in humans. Although 
acquisition of an ExPEC strain by the host is a prerequisite for ExPEC infection, it is not  
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the rate-limiting step, which instead is entry of a colonizing ExPEC strain from its site of 
colonization (e.g., the colon, vagina, or oropharynx) into a normally sterile extraintestinal 
site (e.g., the urinary tract, peritoneal cavity, or lungs). ExPEC strains have acquired 
genes encoding diverse extraintestinal virulence factors that enable the bacteria to cause 
infections outside the gastrointestinal tract in both normal and compromised hosts 39  . 
E. coli is the most common enteric gram-negative species to cause extraintestinal 
infection in ambulatory, long-term-care, and hospital settings. 39 
 
Bacteremia caused by E.coli 
                        E. coli bacteremia can arise from primary infection at any extraintestinal 
site. In addition, primary E. coli bacteremia can arise from percutaneous intravascular 
devices or can result from the increased intestinal mucosal permeability seen in neonates 
and in the settings of neutropenia and chemotherapy-induced mucositis, trauma, and 
burns. Roughly equal proportions of bacteremia cases originate in the community and in 
the hospital. E. coli and Staphylococcus aureus are the most common clinically 
significant blood isolates; E. coli, which is isolated in 17 to 37% of cases, is the gram-
negative bacillus most often isolated from the blood in the ambulatory setting as well as 
in most long-term-care and hospital settings. Isolation of E. coli from the blood is almost 
always clinically significant and typically is accompanied by the sepsis syndrome, severe 
sepsis (sepsis-induced dysfunction of at least one organ or system), or septic shock,  
manifesting with hypotension and fever (in some cases, with hypothermia rather than 
fever). It may be complicated by uremia, hepatic failure, acute respiratory distress 
syndrome, stupor or coma, and death. Non–life-threatening bacteremia may manifest as a  
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sudden onset of fever and chills, tachycardia, tachypnea, and mental confusion. The 
urinary tract is the most common source of E. coli bacteremia, accounting for two-thirds 
of episodes40. Bacteremia from a urinary tract source is particularly common with 
pyelonephritis, urinary tract obstruction, or instrumentation in the presence of infected 
urine. The abdomen is the second most common source, accounting for 25% of episodes.  
Although obstructive biliary tract disease (stones, tumor) and overt disruption of bowel 
are responsible for many of these cases, some abdominal sources (e.g., abscesses) are 
remarkably silent clinically and require identification via imaging studies (e.g., computed 
tomography). Soft tissue, bone, and pulmonary infections are the next most common 
sources for bacteremia. 
 
Klebsiella 38 
                        The genus Klebsiella belongs to the tribe Klebsiellae, a member of the 
family Enterobacteriaceae. The organisms are named after Edwin Klebs, a 19th century 
German microbiologist. Klebsiellae are nonmotile, rod-shaped, gram-negative bacteria 
with a prominent polysaccharide capsule. This capsule encases the entire cell surface, 
accounts for the large appearance of the organism on gram stain, and provides resistance 
against many host defense mechanisms.  
                           Members of the Klebsiella genus express 2 types of antigens on their 
cell surface. The first is a lipopolysaccharide(O antigen); the other is a capsular 
polysaccharide(K antigen). Both of these antigens contribute to pathogenicity. About 77 
K antigens and 9 O antigens exist 41. The structural variability of these antigens forms the  
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basis for classification into various serotypes; the virulence of all serotypes appears to be 
similar.  
                           The genus was originally divided into 3 main species based on 
biochemical reactions. Today, 7 species with demonstrated similarities in DNA 
homology are known. These are 
 (1) Klebsiella pneumoniae, 
 (2) Klebsiella ozaenae,  
(3) Klebsiella rhinoscleromatis,  
(4) Klebsiella oxytoca,  
(5) Klebsiella planticola,  
(6) Klebsiella terrigena, and  
(7) Klebsiella ornithinolytica.  
K pneumoniae is the most medically important species of the group. K oxytoca and K 
rhinoscleromatis have also been demonstrated in human clinical specimens. In recent 
years, Klebsiellae have become important pathogens in nosocomial infections. 
                       Klebsiellae are ubiquitous in nature. Carriage rates vary with different 
studies. Klebsiellae may be regarded as normal flora in many parts of the colon and 
intestinal tract and in the biliary tract. Oropharyngeal carriage has been associated with 
endotracheal intubation, impaired host defenses, and antimicrobial use. In healthy 
humans, K. pneumoniae colonization rates range from 5 to 35% in the colon and from 1 
to 5% in the oropharynx; the skin is usually colonized only transiently. They may also  
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colonize sterile wounds and urine. Organisms can spread rapidly, often leading to 
nosocomial outbreaks. 
The spectrum of clinical syndromes includes pneumonia, bacteremia, thrombophlebitis, 
urinary tract infection (UTI), cholecystitis, diarrhea, upper respiratory tract infection, 
wound infection, osteomyelitis, and meningitis. Sepsis and septic shock may follow entry 
of organisms into the blood from a focal source. The presence of invasive devices,  
contamination of respiratory support equipment, use of urinary catheters, and use of 
antibiotics are factors that increase the likelihood of nosocomial infection with Klebsiella 
species.  
Bacteremia caused by Klebsiella pneumoniae 
                         Klebsiella infection at any site can result in bacteremia. Infections of the 
urinary tract, respiratory tract, and abdomen each account for 15 to 30% of Klebsiella 
bacteremias. Intravascular device–related infection is another important source (5 to 
15%). Surgical site infection and other miscellaneous infections account for the rest. 
Klebsiella is one of the agents that causes sepsis neonatorum and bacteremia with fever 
and neutropenia. Like enteric GNB in general, Klebsiella rarely causes endocarditis or 
endovascular infection. 
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Prevalence studies 
Indian data: 
                          In a dissertation by Mathai D, in our centre,42 among 672 patients with 
blood stream , skin and soft tissue and closed space infections, caused by Gram-negative 
group study pathogens, 37.9% was community acquired and 28.8% was nosocomial. 
ESBL rate among community acquired - E.coli was 26.2%, 25% in Klebsiella spp., and 
32.2% in Enterobacter spp. In the nosocomial group 72.8% was due to ESBL E.coli, 
26.4% Klebsiella spp and 25.8% Enterobacter spp.  Overall, among the Gram negative 
group a significant difference in the frequency of nosocomial occurrence of infection 
caused by ESBL E.coli was seen when compared to non ESBL-E.coli.   The total number  
of deaths (n=36) due to Gram- negative infections was 5.11% with 75% of them caused 
by ESBLs. Mortality due to ESBL causing blood stream infections was 47.2% and the 
remainder occurring among those with skin, soft tissue and closed space infections.. 
Early death occurred among those infected with ESBL E.coli. This significant difference 
was not seen among the infections caused by Klebsiella spp. 
                        In a study of  678 Gram negative bacteria from various clinical samples 
obtained from indoor patients admitted to the All India Institute of Medical Sciences, 
New Delhi during March to June 2001, 458 (68%) were found to be ESBL producers. 
Among the bacterial species, ESBL production was most common in Klebsiella spp. 
(80%). The proportion of ESBL positive isolates was highest from intensive care units 
(79%), followed by Medical Oncology (75%), Medical (54%) and Surgical wards 
(50%).4  
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                     In a study done at the Departments of Microbiology, King George's Medical 
College, Lucknow, 43  ESBL was detected in 86.6% of Klebsiella spp., 73.4% of 
Enterobacter spp. and 63.6% of Escherichia coli strains. It was also observed that 74.4-
80.9% of these ESBL producers were resistant to cefotaxime and 47.6-59.5% were 
resistant to ceftazidime in routine susceptibility testing. Some ESBL producers (36.3-
61.5%) were found to be susceptible to either or both cephalosporins used in this study. 43 
                      In a study done among septicaemic neonates in neonatal intensive care units 
(NICU) at  Post Graduate Department of Microbiology, King George's Medical 
University, Lucknow, India,44 a total of 100 clinical isolates of Klebsiella spp isolated 
from 2995 blood samples of suspected cases of neonatal septicaemia were 
studied.Antimicrobial susceptibility was determined by Kirby- Bauer's disc diffusion 
method. Resistance pattern of ESBL producers and non-ESBL producers was compared. 
58% of Klebsiella isolates were positive for ESBL production. Almost all the isolates 
were sensitive to imipenem and meropenem. Drug resistance was found to be 
significantly more common in ESBL producing isolates than in non-ESBL producers.44  
                        In a study done at National Institute of Communicable Diseases, New 
Delhi in 2003, 4551 K. pneumoniae isolates were confirmed from samples from pus, 
wound, pleural fluid, urine and tracheal aspirate of 395 patients attending respiratory, 
urology and burns wards. Antimicrobial susceptibility was carried out by Kirby Bauer's 
disc diffusion technique using NCCLS criteria. A screening of ESBL production was 
done by Double-disc synergy test (DDST) and using E-test ESBL strips. The frequency 
of resistance among K. pneumoniae for the cephalosporins (cefoxitin, cefuroxime,  
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cefotaxime, ceftazidime, and cefepime) and non-cephalosporins (aztreonam, piperacillin, 
chloramphenicol and trimethoprim-sulfamethoxazole) were in the range of 39.2-88.0% 
and 51.0-90.2% respectively. A total of 36 (70.6%) of the 51 isolates were could be 
identified as ESBL producers. 
Data from other countries 
                        Despite worldwide use of β-lactam antibiotics, the distribution of the 
enzymes responsible for resistance to oxyimino-cephalosporins and carbapenems is far 
from uniform. Some hospitals in the United States seem to have no ESBLs, whereas in 
other hospitals as many as 40 percent of K. pneumoniae isolates have been reported to be  
 
ceftazidime-resistant as a result of ESBL production. 46,47 their prevalence is higher in 
isolates from intensive care units than in isolates from other hospital sites. 
                        In a study by Winokur et al, 48 of more than 4700 K. pneumoniae isolates, 
the percentage expressing an ESBL phenotype was highest in isolates from Latin 
America (45.4 percent), the Western Pacific (24.6 percent), and Europe (22.6 percent) 
and lowest in strains from the United States (7.6 percent) and Canada (4.9 percent). In 
more than 13,000 isolates of E. coli, the percentages expressing the ESBL phenotype 
were as follows: in Latin America, 8.5 percent; in the Western Pacific, 7.9 percent; in 
Europe, 5.3 percent; in the United States, 3.3 percent; and in Canada, 4.2 percent.48   
                  In another study from the United States, ceftazidime resistance was 
present in 9.6 percent of K. pneumoniae isolates from intensive care units and 6.6 percent 
of isolates from other hospital locations.49A resistant strain or plasmid may cause 
problems in several hospitals locally or involve a large geographic area.50,51 Community  
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clinics and nursing homes have also been identified as potential reservoirs for ESBL-
producing K. pneumoniae and E. coli.52,53 In 1989, non typhoid salmonella strains 
producing CTX-M-2 began to spread among neonatal units in Argentina and to 
neighboring South American countries, and by 2002 this enzyme was present in about 75 
percent of ESBL-producing Enterobacteriaceae in Buenos Aires.54 CTX-M enzymes, 
which are also common in Japan, China, Korea, Taiwan, Vietnam, and India, have bee 
Kingdom55 and have been reported in Eastern Europe, Germany, France, and Spain and 
recently in the United States.56  It is estimated that in the United States, 3 to 4 percent of 
clinical K. pneumoniae and K. oxytoca isolates carry plasmid-mediated AmpC enzymes. 
One particular plasmid-mediated AmpC enzyme, CMY-2, has been responsible for  
increasing resistance to ceftriaxone and other oxyimino-β-lactams in salmonella isolates 
from the United States. In Japan, IMP-type carbapenemases, first detected in Serratia 
marcescens and P. aeruginosa, have spread to other gram-negative bacilli,57 but the 
prevalence of this resistance mechanism is surprisingly low: 1.3 percent in P. aeruginosa 
and less than 0.5 percent in E. coli and K. pneumoniae47,58,59 Considering the broad 
resistance to β-lactam antibiotics that is conferred by carbapenemases and considering 
their presence in Japan for more than a decade, their limited occurrence is reassuring, 
considering the potential for future spread. Worldwide, 99.9 percent of 
Enterobacteriaceae remain susceptible to carbapenems.60 Carbapenemases can, however, 
be associated with lethal infections. In Greece and Italy, outbreaks due to carbapenem-
resistant P. aeruginosa producing VIM-1 carbapenemase were identified in separate 
hospitals and associated with a high mortality rate. 47,61,62  In Brazil, a strain of A. 
baumannii resistant to imipenem and meropenem due to an OXA-type carbapenemase  
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infected eight patients in two hospitals; five of the patients died, despite therapy with 
multiple antibiotics, including polymyxin B.47,63 K. pneumoniae strains with reduced 
susceptibility to carbapenems due to KPC-2 or KPC-3 have been recently reported in 
several hospitals in New York City.64  
 
Risk Factors for Infection: 
                        Reported risks, many of which are linked, include an increased length of 
stay in  the hospital,5,65,66an increased of stay in the intensive care unit,67,68  increased 
severity of illness,5,6,69 the use of a central venous or arterial catheter,5,67,67,67,68,70the use 
of a urinary catheter,67,6,68,69 70 ventilatory assistance,68,6,71 hemodialysis,72 emergency  
abdominal surgery,68 the use of a gastrostomy or jejunostomy tube,5 gut colonization,67  
prior administration of an oxyimino- -lactam antibiotic,5,6,8,73,74,89 and prior 
administration of any antibiotic .5,70,75 
 
Problems in Detection 9 
                         Identifying organisms that are ESBL producers is a major challenge for 
the clinical microbiology laboratory. Due to the variable affinity of these enzymes for 
different substrates and inoculum effect, some ESBL isolates may appear susceptible to a 
third generation cephalosporin in vitro. However, treatment of infections due to an ESBL 
producing organism with third generation cephalosporins may result in clinical failure if 
infection is outside the urinary tract. 1 Cefpodoxime and ceftazidime have been proposed 
as indicators of ESBL production as compared to cefotaxime and ceftriaxone. Hence, a  
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centre where only cefotaxime and ceftriaxone are routinely tested, may have difficulty in 
detecting ESBLs.1 
                       As, these enzymes can be induced by certain antibiotics, amino acids or 
body fluids, organisms possessing genes for inducible β-lactamases show false 
susceptibility if tested in the uninduced state. 76 
                          For ESBL producing bacteria there is a dramatic rise of the minimum 
inhibitory concentration (MIC) for extended spectrum cephalosporins when the inoculum 
is increased beyond that used in routine susceptibility. Some isolates test susceptible at 
the standard inoculum of 10 5 CFU/mL but are resistant at an inoculum of 10 7 CFU/mL. 
Therefore, they may be reported as false sensitive if tested by routine methods. 77  
Sensitivity breakpoints of MIC as designated  by  the Clinical and Laboratory Standards 
Institute(CLSI),78 recommend screening Klebsiella spp. and E. coli isolates with a MIC 
greater than or equal to 2 mg/mL against cefpodoxime, ceftazidime, aztreonam, 
cefotaxime, or ceftriaxone, as potential ESBL producers. Two indicators of ESBLs are an 
8 fold reduction in MIC in the presence of clavulanic acid when using the broth dilution 
and the potentiation of the inhibitor zone by clavulanic acid (>5 mm increase in diameter 
of inhibition zone) when using disc diffusion method. These methods, though useful, may 
not detect those ESBLs that are poorly inhibited by  β-lactamase inhibitors.1 
                        Two recent studies evaluated the ability of clinical laboratories to detect 
and report the presence of ESBLs. A survey in Connecticut 1 found that 21% of 
laboratories fail to detect ESBL producing isolates. A proficiency testing project for  
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clinical laboratories participating in the National Nosocomial Infections Surveillance 
System 1 indicated that as many as 58% laboratories failed to detect and report ESBL 
isolates correctly. These data suggest that improvements in the ability of clinical 
laboratories to detect ESBL are needed.1  
Methods of Detection  
Several tests have been developed to confirm the presence of ESBLs. 
Double disc synergy test  79   
In this test, discs of third generation cephalosporins and amoxicillin-clavulanic acid are 
kept 30 mm apart from center to center on inoculated Mueller-Hinton Agar (MHA). A 
clear extension of the edge of the inhibition zone of cephalosporin towards the 
amoxicillin-clavulanic acid disc is interpreted as positive for ESBL production.  
Three dimensional test80  
                        This test provides the advantage of simultaneous determination of the 
antibiotic susceptibility and the β-lactamase substrate profile. Inoculum produced in this 
method contains between 109 and 1010 CFU/mL of cells that actively produce β-
lactamase. Two types of inocula are prepared, a disc diffusion test inoculum (optical 
density equal to that of 0.5 McFarland standard) and a three dimensional inoculum 
(contain between 109 and 1010  CFU/ml). Plate is inoculated by disc diffusion procedure. 
A circular slit is cut on the agar 4mm inside the position at which the antibiotic discs are 
placed. Conventional (two dimensional) disc diffusion susceptibility test results are 
measured according to the recommendations of the Clinical Laboratory Standard Institute  
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 (CLSI).78 Distortion or discontinuity in the circular inhibition zone is interpreted as 
positive for ESBL production. 
Inhibitor potentiated disc diffusion test 81 
                        Cephalosporin disc is placed on clavulanate containing and with out 
clavulanate containing MHA plates. More than10 mm increase in the zone of inhibition 
on the clavulanate containing MHA plate indicates ESBL production. 
Disk approximation test 76 
                       Cefoxitin (inducer) disc is placed at a distance of 2.5 cm from 
cephalosporin disc. Production of inducible β-lactamase is indicated by flattening of the 
zone of inhibition of the cephalosporin disc towards inducer disc by >1 mm.  
MIC reduction test 1  
                     An 8 fold reduction in the MIC of cephalosporin in the presence of 
clavulanic acid indicates production of ESBL. 
Vitek ESBL Test 82  
                        Four wells containing cards are inoculated. A predetermined reduction in 
growth of cephalosporin well containing clavulanic acid; when compared with the level 
of growth in well with cephalosporin alone indicates presence of ESBL. 
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E-Test83  
                        The E test ESBL strip carries two gradients, on the one end, ceftazidime 
and on the opposite end ceftazidime plus clavulanic acid. MIC is interpreted as the point 
of intersection of the inhibition ellipse with the E test strip edge. Ratio of ceftazidime  
MIC and ceftazidime clavulanic acid MIC equal to or greater than 8 indicates the 
presence of ESBL. 
Disk Diffusion Susceptibility Testing (Kirby-Bauer Method):84 
                        For the Disk Diffusion Test, a carrier (paper disk) impregnated with a 
known amount of antibiotic is placed on the surface of a solid medium, which has 
previously been inoculated with a bacterial suspension of the pathogen to be tested. The 
antibiotic diffuses from the carrier into the medium, producing a concentration gradient. 
Bacterial growth in the vicinity of the carrier only occurs when the 
concentration diffusing from the carrier is no longer sufficient to inhibit bacterial 
replication, or when the pathogen is resistant to the antibiotic in question. If the 
concentrations are sufficient to achieve inhibition, a circular region of no bacterial growth 
develops. This is called the zone of inhibition, figure 4 and the limits are mentioned in 
table 3. 
                        The Clinical and Laboratory Standards Institute (CLSI) has developed 
broth microdilution and disk diffusion screening tests using selected antimicrobial agents 
Each Klebsiella pneumoniae, K. oxytoca, or Escherichia coli isolate should be considered 
a potential ESBL-producer based on disc diameter and MIC parameters, shown in table 4.  
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                      Figure 4. Disk diffusion test 
 
 
Table3. Defined limits for zone of inhibition 
Judgement Inhibition zone 
diameter(mm) 
MIC 
(microgram/ml) 
Sensitive           > 21           <0.5 
Moderately sensitive           18 -21               1 
Resistant           < 17             >2 
 
Table 4.  MIC and Inhibition Zone Criteria for the Detection of ESBLs  
               in K. pneumoniae and E.coli* 
Zone diameter for isolates 
in mm 
MIC in mg/ L Antibiotic  
 Susceptible  ESBL 
producing 
Susceptible  ESBL 
producing 
Aztreonam 30µg ≥22 ≤ 27   ≤8  ≥2  
Cefotaxime 30µg ≥23 ≤27  ≤8  ≥2  
Cefpodoxime 30µg ≥ 21  ≤ 22  ≤8  ≥2  
Ceftazidime 30µg ≥18  ≤ 22  ≤8  ≥2  
Ceftriaxone 30µg ≥21  ≤ 25  ≤8  ≥2  
*adapted from NCCLS document M100-S88 
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 The sensitivity of screening for ESBLs in enteric organisms can vary depending on 
which antimicrobial agents are tested. 78The use of more than one of the five 
antimicrobial agents suggested for screening will improve the sensitivity of detection. 
Cefpodoxime and ceftazidime show the highest sensitivity for ESBL detection.78 
Confirmation of ESBL production: 
                       CLSI recommends performing phenotypic confirmation of potential ESBL- 
producing isolates of K. pneumoniae, K. oxytoca, or E. coli by testing both cefotaxime 
and ceftazidime, alone and in combination with clavulanic acid. Testing can be 
performed by the double disk diffusion test. 
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Disk Approximation or Double Disk Method : 85 
                      The disk approximation method uses either multiple target disks, or a single 
cefpodoxime disk, and a clavulanic acid disk. Disk content and the disk placement must 
follow a validated method.86 
                    A Mueller-Hinton agar plate is inoculated with a suspension made from an 
overnight blood agar culture of the test strain as recommended for a standard disk 
diffusion susceptibility test. Disks containing the standard 30 µg of ceftazidime, or 
ceftriaxone, or aztreonam, or 10 µg of cefpodoxime are placed 15 mm apart (edge to 
edge) and from an amoxicillin-clavulanic acid disk containing 10 µg of the latter 
compound. The disk edge-to-edge distance recommended here is that reported7 as having 
greater sensitivity than the previous distance of 20 to 30 mm. 
                       Following incubation for 16-20 hours at 35o C, any enhancement of the 
zone of inhibition between a β-lactam disk and that containing the β-lactamase inhibitor 
is indicative of the presence of an ESBL. 
 
    
                    Precise placement of the disks, correct storage of the clavulanate-containing 
disks, and performance of appropriate control tests are critical to the sensitivity of the 
disk approximation method.87  
                       This method seems to work well for ESBL-producing isolates of K. 
pneumoniae and E. coli but not with Enterobacter or Morganella isolates. K. pneumoniae  
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ATCC 700603 (positive control) and E. coli ATCC 25922 (negative control) are used for 
quality control of ESBL tests. The phenotypic confirmatory test does not detect all 
ESBLs. Some organisms with ESBLs contain other β-lactamases that can mask ESBL 
production in the phenotypic test, resulting in a false-negative test. These β-lactamases 
include AmpCs and inhibitor-resistant TEMs (IRTs). Hyper-production of TEM and/or 
SHV β-lactamases in organisms with ESBLs also may cause false-negative phenotypic 
confirmatory test results. Currently, detection of organisms with multiple β-lactamases 
that may interfere with the phenotypic confirmatory test can only be accomplished using 
isoelectric focusing and DNA sequencing, 
Clinical and Laboratory Standards Institute guidelines 2006 :78,88 
                        Strains of Klebsiella spp, E. coli and Proteus mirabilis that produce ESBL 
may be clinically resistant to therapy with penicillins, cephalosporins or aztreonam 
despite apparent invitro susceptibility to some of these agents, table 5. Some of these 
strains will show zones of inhibition below the normal susceptible population, but above 
the standard break points for certain extended spectrum cephalosporins or Aztreonam; 
such strains may be screened for potential ESBL production by using the screening break  
points as recommended by CLSI .Other strains may test intermediate or resistant by 
standard breakpoints to one or more of these agents. In all strains with ESBL, the zone 
diameters for one or more of the extended spectrum cephalosporins should increase in the 
presence of clavulanic acid as described in the phenotypic confirmation test. For all 
confirmed ESBL producing strains, the test interpretation should be reported as resistant 
for all penicillins, cephalosporins and aztreonam. 
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 Reporting of results 78 
1. Susceptible (S)  
                        The “susceptible” category implies that isolates are inhibited by the 
usually achievable concentrations of antimicrobial agent when the recommended dosage 
is used for the site of infection.  
2. Intermediate (I)  
                        The “intermediate” category includes isolates with antimicrobial agent 
MICs that approach usually attainable blood and tissue levels and for which response 
rates may be lower than for susceptible isolates. The intermediate category implies 
clinical efficacy in body sites where the drugs are physiologically concentrated (e.g., 
quinolones and β-lactams in urine) or when a higher than normal dosage of a drug can be 
used (e.g., β-lactams). This category also includes a buffer zone, which should prevent 
small, uncontrolled, technical factors from causing major discrepancies in interpretations, 
especially for drugs with narrow pharmacotoxicity margins.  
 
3. Resistant (R)  
                        The “resistant” category implies that isolates are not inhibited by the 
usually achievable concentrations of the agent with normal dosage schedules, and/or that 
demonstrate zone diameters that fall in the range where specific microbial resistance  
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mechanisms (e.g., β-lactamases) are likely, and clinical efficacy of the agent against the 
isolate has not been reliably shown in treatment studies. 
 
Antibiotic susceptibility 
                       There is an alarming rise in ESBL production among Klebsiella and E coli 
strains and high rate of resistance to a wide range of cephalosporin and non-
cephalosporin group of antimicrobials. A study was done to evaluate the ESBL 
production and in-vitro susceptibility of K. pneumoniae isolates from the National 
Institute of Communicable Diseases in New Delhi in 2004.45 The bacterial isolates 
collected during 2003 included 51 K. pneumoniae biochemically confirmed isolates from 
395 patients admitted in various wards of a major hospital in New Delhi. The isolates 
were from pus, wound, pleural fluid, urine and tracheal aspirate of patients attending 
respiratory, urology and burns wards. The frequency of resistance among K. pneumoniae 
for the cephalosporins (cefoxitin, cefuroxime, cefotaxime, ceftazidime, and cefepime) 
and non-cephalosporins (aztreonam, piperacillin, chloramphenicol and trimethoprim-
sulfamethoxazole) were in the range of 39.2-88.0% and 51.0-90.2% respectively. 14 
different antimicrobial resistance profiles were recognized ranging from resistance to  
only four (n=6, 11.7%) to as many as ten (n=9, 17.7%). (70.6%) 36/51 of the strains 
produced ESBL that correlates with the high frequency of multi-drug resistant K. 
pneumoniae. 
                        In a multicentric study, done in south India by Mathai D  ,42 at CMCH and 
other sentry centers, Gram-negative study pathogens including MDR (resistance to ≥  
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three classes) strains showed excellent  susceptibility   to imipenem and meropenem 
(>95%). All ESBLs were MDR with high resistance rates (>90%) to β-lactam- β-
lactamase inhibitor combination, fourth generation cephalosporins, quinolones and 
aminoglycosides. Among non ESBLs high susceptibility (>90%) to β-lactam- β-
lactamase inhibitor combination, fourth generation cephalosporins, quinolones and 
aminoglycosides was observed. The antibiogram of ESBL producing Gram negative 
study pathogen among ICU and non ICU settings seen were similar. There was no 
difference in the susceptibility pattern of the community and hospital associated Gram-
negatives. 
Treatment 
                        Of all the available β-lactams, carbapenems are the most effective and 
reliable, as they are highly resistant to the hydrolytic activity of all ESBL enzymes, due 
to the trans-6 hydroxy ethyl group.1 Meropenem is the most active with MICs generally 
lower than those of imipenem (0.03-0.12mg/mL Vs 0.06-0.5mg/mL). Several new 
carbapenems, ertapenem and faropenem are being studied in the various phases of 
clinical trials.1 Some infections due to organisms testing resistant to ceftazidime but  
 
susceptible to cefotaxime or ceftriaxone, have responded to treatment with these alternate 
cephalosporins. However, MICs of these agents rise dramatically as the inoculum is 
increased.34 
                        A few β-lactams, 7α methoxy cephalosporins such as cefoxitin,  
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cefmetazole, cefotetan and latamoxef are often effective in the treatment of infections 
caused by enzyme producing bacteria. However, cephamycins should be used with 
caution because of the relative ease with which clinical strains decrease expression of 
outer membrane proteins.89                                
                        Although ESBL activity is inhibited by clavulanic acid, the only infections 
that may be treated safely with β- lactam/β-lactamase inhibitor combination are those 
involving the urinary tract. In this instance, β- lactamase inhibitor concentration is high 
enough to counteract the hydrolytic activity of ESBLs. 16 
                        By inhibiting ESBL, β-lactamase inhibitors appear to impair the 
emergence and spread of Klebsiella carrying resistance plasmids. Furthermore, 
administration of inhibitors may exert in vitro pressure on ESBL, thereby facilitating 
their reverse mutation to less harmful enzymes.71 Clavulanic acid appears more efficient 
than sulbactam, it takes about eight times more sulbactam to obtain a protection similar to 
that given by clavulanic acid 47.Non β-lactam antimicrobial agents (aminoglycosides, 
fluoroquinolones) may be beneficial, however, co resistance rates against these agents are 
frequent.1  
 
Outbreak Control 
                        In outbreak situations, successful control has usually involved both 
restriction of the use of oxyimino-β-lactams and the institution of barrier precautions 
(hand washing, gloves, and gowns) for patients with infection or colonization..6,90,91  
 79
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 80
Successful control with the use of strict isolation procedures without limitations on 
antibiotic use has also been reported.92 Substitution of imipenem,91 piperacillin–
tazobactam,93 or cefepime–amikacin94 as the antibiotic of choice for empirical therapy 
has been followed by decreased isolation of ESBL-producing organisms.  
                        Antibiotic substitutions can, however, have unintended consequences. In 
an outbreak of infection with K. pneumoniae resistant to other β-lactam antibiotics, 
increased use of imipenem was followed by the emergence of imipenem-resistant K. 
pneumoniae that produced an AmpC enzyme (ACT-1) and was missing an outer-
membrane porin 64,95. At the same hospital, increased use of imipenem also led to the 
emergence of imipenem-resistant A. baumannii. 96 
                         A report from Pondicherry Institute of Medical Sciences, Kalapet, 
Pondicherry in 200497 describes an outbreak of ESBL positive K.pneumoniae in a 
neonatal intensive care unit, which occurred over a period of 20 days resulting in death of 
8 out of 10 neonates affected. The outbreak started with the isolation of K. pneumoniae 
from a preterm baby with severe respiratory distress and within a period of three weeks 
ten neonates developed K.pneumoniae septicaemia. Isolation of the septicaemic neonates 
was done to control spread of K.pneumoniae in the neonatal intensive care unit. 
Subsequent screening of the environment yielded K.pneumoniae from breast pump,  
breast milk storage bottle and refrigerator.  Antibiotic susceptibility testing of all clinical 
and environmental isolates showed a similar antibiogram. The breast pump and the milk 
storage bottle were identified as the most probable source responsible for the outbreak. 
Sterilization of breast pump and storage bottles subsequently controlled the outbreak.  
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Therefore institution of barrier precautions (hand washing, gloves, and gowns) for 
patients with infection or colonization is essential in controlling an outbreak of an ESBL 
producing organism. 
Scoring systems 
PITT s bacteremia score :36  
                       This is a previously validated scoring system to assess the severity of the 
illness for prognostication. Severity of illness was assessed by  this grading system that 
evaluated mental status (Disoriented -1, Stupor -2, Coma – 4 points ); Fever ( >= 37.6º C 
and < 40 º C -1 point ; >=40 º C -2 points ); hypotension ( drop in systole  20 mm Hg or 
diastolic > 10 mm Hg or on intravenous pressor agents -2 points );Mechanical ventilation 
-2 points and cardiac arrest –4 points. Patients accumulating 4 or more points were 
defined as severely ill. This grading system has previously been shown to be highly 
predictive of outcome in previous studies of Klebsiella and Pseudomonas bacteremia.7, 
36,98,99  The scoring system is appended, appendix 1.  
        SAPS II score :100-102   
                         This is a standard scoring system used commonly in the ICU s of France, 
where it was first validated. SAPS II includes 15 variables including 12 physiology  
variables. SAPS II includes 15 variables including 12 physiology variables using which, 
the predicted mortality could be calculated.  
The variables are as follows:  
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Age, type of admission (scheduled surgical , unscheduled surgical, or medical), 
underlying disease condition (AIDS, metastatic cancer, and hematologic malignancy), 
Glasgow Coma Scale(GCS), systolic blood pressure(SBP), heart rate, temperature,  PaO2/ 
FiO2 on ventilatory support, urine output, serum urea/ blood urea nitrogen (BUN), WBC 
count, serum potassium, sodium, bicarbonate and bilirubin. 
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                       MATERIALS AND METHODS  
 
 
              
Study Setting: 
                       The study was conducted in Christian Medical College Hospital, Vellore, a 
2500 bedded academic medical center in South India with an average of 1815 inpatients 
and approximately 3500 out- patient visits every day. 
 
Study design: 
                        This was a prospective cohort study. 
Subjects:         
                        The study recruited all sequentially encountered patients older than 16 
years with Klebsiella or E. coli bacteremia who were admitted in various wards and 
Intensive care units of this hospital during the study period. We recruited a total of 131 
patients over a 4 month period. 
Inclusion criteria: 
1. Isolation of  E. coli or Klebsiella from blood culture samples and  
2. Willingness to participate in the study. 
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Exclusion criteria:  
1. Patients aged less than 16 years, 
2. Outpatients , 
3. Bacteremias of polymicrobial etiology, 
4. Patients unwilling for inclusion in the study. 
Methodology: 
                        A written informed consent was taken from either the patient, or from the 
legal guardian in those with altered mental status, prior to enrollment. All patients with E 
coli and Klebsiella bacteremia were evaluated within 48 hours of detection of a positive 
blood culture. Bacteremias of polymicrobial etiology were not included. 
                        Blood culture was taken at the onset of fever by venupuncture from a 
peripheral vein after adequate preparation of the skin with povidone iodine (Betadine). A 
minimum of 5 ml of blood was inoculated into a blood culture bottle (BacT/ALERT) 
which is used with the BacT/ALERT microbial detection system in qualitative 
procedures for enhanced recovery and detection of aerobic and facultative anaerobic 
micro organisms. The blood culture bottles were then transported to the department of 
Microbiology where culture and sensitivity tests were done. In all patients only the first 
episode of bacteremia was included for further analysis. 
                        A study form was completed which included the patients demographic 
details, co-morbidities and the possible source of infection (community acquired or 
nosocomial). The history of prior antibiotic use and the details of antibiotics used for the  
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current episode of bacteremia were noted. The antibiotics were prescribed by the treating 
physician and the choice was not influenced by the study. 
                  Severity of acute illness was assessed at the time of the positive blood culture 
by using the PITT bacteremia score,99,103  which is a validated scoring system that is 
based on mental status, vital signs, requirement for mechanical ventilation, and recent 
cardiac arrest. Severity of illness was graded within 48 hours of taking the blood culture. 
Patients accumulating 4 or more points were defined as severely ill. The scoring system 
is included under annexure 1.  
                        Severity of illness in patients in the intensive care unit at the time of 
bacteremia was assessed by using the SAPS II scoring system,100-102,which includes 15 
variables including 12 physiological variables. These were assessed with in 48 hours of 
detection of a positive blood culture for Klebsiella or E coli. Using these variables, the 
predicted mortality was for the current illness was calculated for all patients admitted in 
the various ICU s (MICU, SICU, and TICU) at the time of detection of bacteremia. The 
SAPS II is shown under Annexure 2. Calculation of the score was done by the help of a 
SAPS II scoring calculator available on line102. 
                  The primary source of bacteremia was attributed to a urinary tract, intra-
abdominal focus, and pneumonia or, if a focus could not be identified, classified as a 
primary bloodstream infection. The primary source of bacteremia was localized to the 
above sites if the same organism could be isolated from a fluid specimen from that site or 
based on clinical signs and imaging studies.  
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Follow up:  
                        The patients were followed up for 2 weeks after the diagnosis of 
bacteremia to assess the clinical outcome. 
Microbiological methods: 
                        The blood culture sample taken from the study patients at the onset of 
fever were inoculated into the BacT/ALERT blood culture bottles, which contain 22 ml 
of complex culture media and 8 ml of a 6.5 % charcoal suspension. An inoculated bottle 
is placed into the instrument where it is incubated and continuously monitored for the 
presence of micro organisms. If micro organisms are present in the test sample, carbon 
dioxide is produced as the organisms metabolize the substrates in the culture medium and 
the colour of the gas permeable sensor installed at the bottom of the culture bottle 
changes from blue green to yellow. If a positive blood culture is detected, it is taken out 
of the machine and a gram stain done. Gram negative bacilli are inoculated into Blood 
agar, Mc Conkey agar and Lysine agar tube and direct antibiotic susceptibility testing is 
done. Antibiotic susceptibility was tested in all the blood culture isolates which grew 
Klebsiella and E coli by the disc diffusion test, which is the initial screening test for 
production of ESBL. All the isolates resistant to either cefotaxime or ceftazidime by the 
disc diffusion test were tested for phenotypic confirmation of ESBL production, by the 
double disc diffusion test according to the CLSI performance standards current as of 
200678,88.  The criteria for classification as ESBL producing isolate was a  > 5 mm 
increase in a zone diameter for either antimicrobial agent tested in combination with 
clavulanic acid versus its zone when tested alone. E coli ATCC25922 and Klebsiella 
pneumoniae ATCC700603 strains were used as control organisms throughout the study.  
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The results of culture sensitivity were reported as Susceptible(S), Intermediate(I) and 
Resistant(R)   based on CLSI guidelines.78 
 
Statistical methods: 
 
              Data entry was done using the Statistical Package for the Social Sciences 
(SPSS) software package (version 11). Descriptive statistics were calculated using SPSS 
software. Chi-square test was used for comparison of categorical variables. Odds ratio 
(OR) and confidence intervals (CI) were calculated and a ‘p’ value less than 0.05 was 
considered statistically significant. All reported p values are two-sided. Univariate 
analysis was performed to assess the risk factors for clinical outcome among he study 
patients. 
 
                        The study design and methods were approved by the Fluid Research 
Committee, Christian Medical College, Vellore 
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Definitions: 
 Nosocomial bacteremia: defined as Klebsiella spp and E.coli bacteremia 
occurring among patients more than 48 hours after admission to CMCH or 
another hospital or among those patients who had an invasive procedure done 
(minor surgical procedure, intravenous administration of drugs or placement of a 
urinary catheter) and the bacteremia was attributable to that procedure. 
 An episode of bacteremia is defined as the period of 14 days from the time of 
collection of the first blood culture positive for the above bacteria. 
 Previous antibiotic therapy is defined as antibiotics given for at least 2 days 
within the 14 days before an episode of   Klebsiella spp or E. coli   bacteremia. 
 Mortality was death from any cause within 14 days from the date of the first 
positive blood culture for Klebsiella spp and E. coli.  
 An appropriate antibiotic was defined as an antibiotic  to which the bacterial 
isolate was susceptible in vitro. 
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                               Table 5  : Baseline characteristics 
Characteristic Data  
Demographic data 
Median age  49(years) 
Male 78(59.54) 
Female 53(40.46) 
Primary department to which patient was admitted n(%) 
General  Medicine 44(33.59) 
Hematology 21(16.0) 
Other medical specialties 20(12.27) 
Gastroenterology 16(12.2) 
General surgery 17(12.96) 
Other surgical specialties 13(  9.92) 
Source of bacteremia 
Urinary tract 59(45.04) 
Intra abdominal  29(22.14) 
Pneumonia   7(  5.34) 
Undetermined 36(27.48) 
Co morbidities 
Type II diabetes mellitus 56(42.7) 
Hypertension 28(21.4) 
Chronic renal failure 11(8.4) 
Chronic liver disease 13(9.9) 
Solid tumors 10(7.6) 
Hematological malignancies 20(15.3) 
HIV infection   4(  3.1) 
Recent surgery 23(17.6) 
Ischemic heart disease   9 ( 6.9) 
Cerebrovascular accident   4(3.1) 
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                                         RESULTS 
 
Population characteristics: 
        One hundred and thirty one episodes of bacteremia were included in 
the study during the period of 4 months from Feb 2007 to May 2007, the baseline 
characteristics are shown in table 5. Seventy eight (59.54%) of the subjects were males. 
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Figure 5 : Department wise distribution of patients 
 
 
 
 
Figure 6. Comorbidity profile 
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The patients were admitted to the various departments, shown in figure 5. 
Out of the 131 episodes of bacteremia, there were 10 admissions to the Intensive care 
units (8 in MICU & 2 in SICU) and the rest, in various wards of the hospital. The primary 
department from which the patients were admitted to the ICU is shown in table 6. 
 
Table 6. ICU admissions 
   Department No. of admissions 
General Medicine                  4 
General surgery                  2 
Medical specialties                  2 
Surgical specialties                   2 
 
 
The comorbidity profile is shown in figure 6.  The most common co-
morbid condition was diabetes mellitus type 2, seen in 56(42.7%) patients.                 
Multiple co-morbidities (2 or more) were seen in 39.7 % (52/131) of   patients.                    
45.8 % (60/131) of the patients had only 1 co-morbidity while   14.5 5% (19/131) did not 
have any. 
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Figure 7. Source of infection 
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The most common primary source of the bacteremia was the urinary tract, 
seen in 59(45.04%) patients. An intra-abdominal source was identified in 29(22.14%) 
patients, and pneumonia was the source of bacteremia in 7(5.34%). In 36(27.48%) 
patients, the source could not be identified. This is shown in figure 7.  
Majority of patients with bacteremia of undetermined origin had a 
hematological malignancy where primary blood stream infection is well known to occur. 
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Figure 8: Distribution -Community acquired Vs Nosocomial bacteremia 
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Figure 9: ESBL production in the 131 episodes of bacteremia 
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Eighty two (62.6%) of the episodes of bacteremia were nosocomially 
acquired, figure 8. 
The comparison of comorbidity profile of patients with nosocomial and 
community acquired infections is shown in table 7. ESBL production among these 
isolates is shown in figure 9. 
 
Nosocomial infections were significantly more common in patients who 
had undergone recent surgery (p=0.002) and in those with solid organ tumors (p = 0.011). 
 
Table 7: Comparison of comorbidity profile and source of infection between   
              Nosocomial and Community acquired bacteremia. 
 
Comorbidity  Nosocomial infection 
          n = 82 
Community acquired 
infection 
          n  = 49 
 
p value 
Diabetes Mellitus 31(37.8) 25(51.0) 0.139 
Chronic renal failure  8(9.8) 3(6.1) 0.468 
Chronic liver disease  6(7.3) 7(14.3) 0.197 
Hypertension 17(20.7) 11(22.4) 0.817 
Solid tumors 10(12.2) 0 (0) 0.011 
Hematological malignancy 15(18.3) 5(10.2) 0.213 
HIV infection 3(3.7) 1(2.0) 0.603 
Ischemic heart disease 5(6.1) 4(8.2) 0.651 
Cerebrovascular accident   2(2.43 ) 2(4.1) 0.597 
Recent surgery 21(25.6) 2(4.1) 0.002 
Source of infection 
Urinary tract 31(37.8)               28(57.1)        0.154 
Intra- abdominal 19(23.2)               10(20.4)        0.154 
Pneumonia 5(6.1)                 2(4.1)        0.154 
Undetermined  27(32.9)                 9 (18.4)        0.154 
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Figure 10 : Percentage of bacteremias caused by E coli and Klebsiella 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8.  Primary source of bacteremia. 
 
Organism     E.coli   n (%) Klebsiella  n (%) 
Urinary tract        59(57.8)        0 
Intra- abdominal        17(16.7)      12(41.4) 
Pneumonia          3(2.9)        4(13.8) 
Undetermined        23(22.6)      13(44.8) 
Total        102(100)      29(100) 
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Microbiological data: 
 
E coli caused 102(77.86%) of the episodes of bacteremia and Klebsiella 
29(22.14%), shown in figure 10, the source of bacteremia for these two groups is shown 
in table 8. 
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Figure 11. ESBL producing isolates. 
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In the initial screening test by disc diffusion, 73.5% of E coli isolates and 
72.4% of Klebsiella isolates were resistant to Cefotaxime and Ceftazidime, shown in 
figure 11 and all these  isolates were confirmed to produce ESBL by the double disc 
diffusion test. 
 
The sensitivity of the E coli and Klebsiella isolates to Carbapenems was 
99.2 %, to the 3rd and 4th generation Cephalosporins 26.7%, to the beta lactams and beta 
lactamase inhibitors, ranged between 18.3 to 32.8%. 
The resistance profile of all the isolates to the common antibiotics is 
shown in figures 12, 13 and 14. 
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Figure 12..Antibiotic resistance profile for all isolates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
73.3 73.3 73.3
61.8
50.4 51.9
73.3
81.7
67.2
0.8 0.8
0
10
20
30
40
50
60
70
80
90
P
er
ce
nt
ag
e 
%
C
ef
ot
ax
im
e
C
ef
ta
zi
di
m
e
C
ip
ro
flo
xa
ci
n
G
en
ta
m
ic
in
N
et
ilm
ic
in
A
m
ik
ac
in
Pi
pe
ra
ci
lli
n 
- T
az
ob
ac
ta
m
 
Ti
ca
rc
ill
in
C
ef
ap
er
az
on
e-
 S
ul
ba
ct
am
Im
ip
en
em
M
er
op
en
em
% resistant
 110
 
 
 
 
 
 
Figure 13.Antibiotic resistance profile for ESBL producing isolates: 
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Figure 14. .Antibiotic resistance profile for non ESBL producing isolates 
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           Figure 15. ESBL producing isolates 
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Table 9. ESBL Vs non ESBL, characteristics 
 
Patient characteristics ESBL producing isolates 
96(100 %) 
Non ESBL producing isolates 
35(100 %) 
p 
Median age (years)  50 45 0.508
Sex (M:F) 61:35 17:18 0.122
Primary source 
Urinary tract   44(45.8%) 15(42.9%) 
Intra abdominal   19(19.8%) 10(28.6%) 
Pneumonia  7(7.3%)                    0 
Undetermined    26(27.1%) 10(28.6%) 
0.319
 
Nosocomial infections n(82)               70                   12 <0.001
Comorbidity 
Diabetes mellitus 44(45.8) 12(34.3) 0.237
Chronic renal failure 8(8.3) 3(8.6) 0.965
Chronic liver disease 7(7.3) 6(17.1) 0.095
Hypertension 21(21.9) 7(20) 0.817
Solid tumors 7(7.3) 3(8.6) 0.807
Hematological malignancy 14(14.6) 6(17.1) 0.719
HIV infection 3(3.1) 1(2.9) 0.937
Ischemic heart disease 5(5.2) 4(11.4) 0.213
Cerebrovascular accident 2(2.1) 2(5.7) 0.285
Recent surgery 17(17.7) 6(17.1) 0.940
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ESBL production was seen in 96(73.28%) patients (figure 15). ESBL 
production was observed in 75 out of 102(73.5%) patients with E.coli bacteremia as 
compared to 21 out of 29(72.4%) with Klebsiella bacteremia, figure11. This difference 
was not statistically significant (p=0.905). 
Bacteremia due to ESBL producing E coli and Klebsiella spp were 
significantly more common in nosocomially acquired infections when compared to 
community acquired infections(85.37% Vs 53.06% p= <0.001). There was no significant 
difference in the median age, sex ratio or co morbidity profile among patients with and 
with out ESBL producing bacteremias, table 9. 
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Figure 16. Use of antibiotics over the previous two weeks. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: ESBL production in relation to use of prior antibiotics 
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Prior antibiotic use: 
 
Thirty nine (29.8%) patients gave history of antibiotic use in the preceding 
two weeks. The most common antibiotics used were 3rd and 4th generation 
cephalosporins 20(51.3%). The others were beta lactams with or without betalactam 
inhibitors 7(17.9%), aminoglycosides15 (38.5%), fluoroquinolones, 13(33.3%), 
carbapenems 3(7.7%) and others, 5(12.8%).  
Bacteremia caused by ESBL producing isolates was significantly higher (p 
= 0.006) among patients who had received any antibiotic in the preceding 2 weeks, table 
10. The breakup according to the individual classes of antibiotics is shown in table 11. 
The prior use of 3rd or 4th generation cephalosporins was associated (p=0.017) with ESBL 
production among isolates of Klebsiella and E coli causing bacteremia. 
                      Table 10  Prior antibiotic use and ESBL production 
p = 0.006 ESBL production Total 
  Yes No   
Used 35 4 39Prior Antibiotic 
  Not used 61 31 92
Total 96 35 131
 
Table 11. Prior antibiotic use and ESBL production- breakdown of antibiotics used 
Prior administration of  ESBL ( n = 96) Non ESBL( n=35) p 
Beta lactam ± Beta lactam inhibitors (7)       6           1 0.445 
Cephalosporins (3rd and 4th generation) (20)      19           1 0.017 
Fluoroquinolones (13)      12           1 0.102 
Aminoglycosides (15)      14           1 0.062 
Carbapenems (3)        3           0 0.292 
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Figure 18. Use of prior antibiotic: 
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Figure 19. Combinations used  
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   The antibiotic combinations are shown in figures 18 and 19. 
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               Figure 20. Choice of initial antibiotic 
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            Figure 21.Combination therapy with two antibiotics 
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Antibiotic choices and combinations used for the initial treatment of the 
bacteremias is shown in figures 20,21 and 22. Monotherapy was chosen in 62 episodes 
(48.06%), the commonest being 3rd and 4th generation cephalosporins in 23.25 % and 
combination therapy in 67 episodes (51.94%). 
 
 
 
 
 
                        Figure  22 . Groups of antibiotics used as the initial therapy 
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         Figure 23. Appropriateness of Initial choice of antibiotics 
 
 
 
                       Figure 24 .Appropriateness according to class of antibiotics 
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Appropriateness of Initial choice of antibiotic: 
 
The antibiotic choice for the bacteremic episode was termed appropriate 
based on the in vitro susceptibility report in 74(56.49%) episodes, figure 23. 
 
The most appropriate choice were carbapenems(41/41). The 
corresponding rates for 3rd and 4th generation cephalosporins was 53.9 %( 41/76), 
aminoglycosides and fluoroquinolones was 55.6 %( 10 / 18) and for betalactams with or 
without betalactam inhibitors was 34.5 %( 10/29), this data is shown in figure 24. 
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                 Figure 25. Out come after 2 weeks 
 
 
 
 
                Figure 26 :Outcome among patients with ESBL producing isolates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
               Table 12. Mortality based on source of infection 
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Outcome measures: 
 
One hundred and twenty two patients were followed up for 14 days from 
the time of diagnosis of a bacteremia. Of the 122,   74.6 %( 91) were alive and 25.4 %( 
31) were dead at 14 days, (figure 25). In those patients admitted to the ICUs, the 
mortality rate was 60% (6 out of 10). This was higher than in those not admitted to the 
ICUs, (p = 0.009). 
ESBL production was the same among patients admitted to the ICU, 
7(70%) and in those admitted to the general wards, 89(73.5%) p = 0.807. There was no 
significant difference between ESBL and non ESBL producing infections with regard to 
mortality ( p 0.953),(figure 26) 
There was no significant difference in the mortality between nosocomial 
Vs community acquired infections (p= 0.443), E coli Vs Klebsiella (p=0.842), 
appropriateness of the initial choice of antibiotic (p= 0.520) or the use of carbapenems as 
initial therapy (p=0.968). Higher mortality was seen in patients with a pneumonia 
(p=0.005),(table 12). 
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Figure 27. Duration of hospital stay 
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Table 13. Duration of hospital stay 
 
 
Total duration of 
hospitalization  
ESBL producing Non ESBL producing 
Mean 20.29 12.86 
Median 15.50 9.00 
Mode 2 9 
Std. Deviation 19.587 14.028 
Range 99 77 
Minimum 1 1 
Maximum 100 78 
Percentiles 
25 8.25 5.00 
50 15.50 9.00 
 
75 22.00 14.00 
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The median duration of hospital stay was 14.00 and the  mean was 18.31± 
18.513 days,(figure 27). The minimum duration was 1 day, with a maximum of 100 days. 
The average duration of hospitalization was higher in patients with 
infections caused by ESBL producing isolates (20.29±19.59 days) as compared to 
patients with infections due to non ESBL strains (12.86±14.03) p=0.042. The median 
duration for the two groups was 15.50 and 9 days respectively. This is shown in table 13. 
The overall duration of stay among patients with nosocomial infections 
(23.63±21.09), was predictably longer than those with community acquired infections 
(9.39±6.95). This was significant at a p value of < 0.001. 
The mean duration of ICU stay was longer in patients with infections 
caused by  ESBL producing isolates , 21.57 ± 22.38 days , as compared to 8.33 ± 5.03 
days, in patients with infections due to sensitive strains. However, this difference did not 
achieve statistical significance ( p = 0.355), probably due to the very small number of 
patients studies, 7 and 3 in the two groups respectively. 
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Table 14 . PITTS bacteremia score 
Mean 1.71 
Median 1.00 
Mode 0 
Std. Deviation 2.585 
Variance 6.684 
Range 11 
Minimum 0 
Maximum 11 
25 .00 
50 1.00 Percentiles 
75 2.00 
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Severity scoring: 
 
The median PITT score was 1.77, with a mean of 1.71 ± 2.585, and a 
maximum value of 11. The PITTS score in patients admitted to the ICUs was 
significantly higher, 4.70 ± 2.31, as compared to the patients admitted in the other wards, 
1.46 ± 2.46, the difference was significant at a p value of < 0.001. Also the PITTS score 
was significantly lower in patients alive at 14 days of follow up, 0.79 ± 1.15, as compared 
to 4.81± 3.45, p <0.001.  
The PITTS score was higher in community acquired infections, 2.33 ± 
2.96, as compared to nosocomial infections, 1.34 ± 2.27, p = 0.049.. 
The PITTS score in patients with ESBL was not significantly higher, 1.83 
± 2.602, as compared to the patients without ESBL, 1.37 ± 2.545, p = 0.368. 
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                                                DISCUSSION   
 
 
                           Extended spectrum β-lactamase production is the defense mechanism 
developed by bacteria in the race for survival. This has largely been aided by faulty and 
inconsistent prescription practices, the world over. The gravity of the situation is more 
obvious in resource poor settings where antimicrobial prescription policies are either not 
in place or not respected. 
                        The need remains to quantify this problem, to identify the risk factors for 
ESBL production, the current antibiotic practices for appropriateness and to assess the 
risk factors for poor clinical outcome among patients with ESBL producing E. coli or 
Klebsiella infection. This has been the main objective of our study. 
 
                       One hundred and thirty one episodes of bacteremia due to E. coli or 
Klebsiella spp were included in the study during the period of 4 months from February 
2007 to May 2007. The reason that we chose bacteremic patients as the study population 
is to avoid the difficulty in differentiating infection and colonization in other samples 
(e.g. sputum, urine, endotracheal aspirate etc). 
                            
                       The commonest primary source of the bacteremia was the urinary tract 
followed by an intra abdominal source. The urinary tract was the most common source of 
infection in other studies also.7 In a significant number of patients the source of 
bacteremia could not be determined. Most of them had a hematological malignancy 
where primary blood stream infection is well known to occur. 
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ESBL production                    
                        With the rapid spread of ESBL producing strains in hospitals all over the 
world, it is necessary to know the prevalence in a hospital so as to formulate a policy of 
appropriate antibiotic therapy and other measures to control the spread of the pathogens.. 
ESBL production was seen in 73.3% of patients with E. coli and Klebsiella bacteremia 
which is higher than the reported prevalence in other hospitals in India and other 
countries. A study done at AIIMS in 2002 showed that 68 % of the Enterobacteriaceae 
isolates produce ESBL and the prevalence in various hospitals abroad range from 3.3% to 
86.6% . In intensive care units in which antibiotic use is heaviest and the potential for 
person to person transmission of organisms is greatest, the prevalence of ESBL 
producing isolates was the same as that in other wards (73.5 % Vs 70 %) in contrast to 
other studies, where ICU admissions were associated with an increased risk of infection 
caused by ESBL producing strains. 7,4 
                       The unusually high prevalence of ESBL producers in the present series 
may partly be explained by the fact that the hospital serves as a tertiary referral center in 
South India and by the fact that most of the ESBL producing isolates were nosocomial in 
origin. ESBL production was seen in 70 out of 82(85.37%) isolates in nosocomial 
infection, as compared to community acquired infections, in which only 26 out of 
49(53.06%) produced ESBL. The high prevalence of ESBL production among 
community acquired isolates is alarming when compared to the prevalence rates in other 
studies. ESBL production among community acquired isolates was only 3.5% in a study 
done by Paterson et al.7 
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        This could be attributable to the following reasons. Excessive use of 3rd and 4th 
generation cephalosporins in the community could increase the prevalence of resistant 
strains. Secondly, due to poor quality of drinking water supplied to the community, spread 
of Enterobacteriaceae is difficult to control. In a study done by Mathai,42 healthy 
volunteers in Jawadhi hills, a rural district of Vellore, who were  antibiotic naïve were 
found to have a 27.1% fecal carriage rates of ESBL producing E. coli.                     
                                
Risk factors for ESBL production            
                         Our data has identified previous treatment with 3rd or 4th generation 
cephalosporins as the most important risk factor associated with ESBL production which 
is in accordance with the study done by Du B et al8 and a study done by Lautenbach et 
al.75 Other studies have also shown an increase in ESBL production with prior 
administration of β-lactam antibiotics containing an oxyimino group.7 However, the 
relatively few patients who received these preclude definitive conclusions about this link.  
Our analyses therefore can only provide hypotheses for further investigation with a larger 
sample size. 
                              Previous antibiotic exposure may lead to resistance to E coli and 
Klebsiella because these antibiotics may exert a selective pressure as to eliminate all the 
sensitive strains rather than through induction of Amp C β-lactamases. 3rd and 4th 
generation cephalosporins represent the most commonly used antibiotic class in hospitals 
therefore exerting a predominant selective pressure for development of resistance. Our 
results confirm the fact that ESBL s may emerge as a result of excessive cephalosporin  
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use and also indicate that interventions designed to restrict cephalosporin use in order to 
reduce the level of antibiotic resistance merits further investigation. Some investigators 
have demonstrated the positive effect of restriction of cephalosporin use on reduction of 
antibiotic resistance, although not without adverse effects.104. It has also been speculated 
that replacing cephalosporins with antibiotics containing ß-lactamase inhibitors (such as 
piperacillin–tazobactam) may help to reduce the occurrence of ESBL-producing 
organisms93,105.  
                      Because many recent resistance problems can be traced to excessive use of 
broad-spectrum antibiotics, antibiotic control policies must be considered mandatory to 
minimize antibiotic resistance. Practical approaches to antibiotic control include 
restricting the use of particular agents, specifically, defining indications for use or cycling 
classes of antibiotics to limit the selective pressure on nosocomial flora. 
 
Antibiotic resistance  
                           A high degree of resistance to multiple classes of antibiotics was noted 
especially to the 3rd and 4th generation cephalosporins and β-lactam and β-lactamase 
inhibitor combinations (73.3% to cephalosporins and ranging between 67.2-81.7 % to β-
lactam and β-lactamase inhibitor combinations).These results were comparable to those 
of a study done at The National Institute of Communicable Diseases in New Delhi in 
2004,45 which showed a high  frequency of resistance among K. pneumoniae for the 
cephalosporins (cefoxitin, cefuroxime, cefotaxime, ceftazidime, and cefepime) and non-
cephalosporins (aztreonam, piperacillin, chloramphenicol and trimethoprim- 
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sulfamethoxazole),in the range of 39.2-88.0% and 51.0-90.2% respectively. 
Aminoglycosides were found to be the next best choice to carbapenems, as resistance 
rates were lower (51.9 % - 61.8 %). Significantly, carbapenem resistance was seen in 1 
patient, who had a nosocomial infection with a ESBL producing strain of E coli, the 
source of infection being the urinary tract. He had an indwelling urinary catheter and 
acquired the infection after 50 days of hospitalization. 
 
Initial antibiotic choice: 
                        With the widespread use of extended-spectrum cephalosporins throughout 
the world, strains that produce ESBLs have been detected on every inhabited continent. 
The emergence and spread of ESBL-producing strains have led to questions regarding the 
optimal therapy for infections caused by ESBL-producing strains. 
                        We evaluated the appropriateness of the initial antibiotics used for each 
episode of bacteremia and found that the antibiotic chosen for the bacteremic episode was   
appropriate in 56.49%.This figure is much less than that seen in a  retrospective study 
done at the Department of Critical Care Medicine, Peking Union Medical College 
Hospital,8 where antibiotic treatment was considered appropriate in 83% of the cases.        
                         In addition to poor choice of antibiotics in approximately half the 
episodes of bacteremia, many patients were given multiple antibiotics as initial therapy (3 
antibiotics in 9.3 % and 4 drugs in 1.6%) which is irrational. In our study, only 48.6 % of 
the patients received monotherapy with the choice being appropriate in only 56.49 %  
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where as studies done in other hospitals have shown 83 % accuracy with 89 % of the 
episodes of bacteremia given monotherapy.8 The need to revise our policy on antibiotic 
administration is evident. 
Clinical outcome 
                            The mortality rate after 14 days of onset of Klebsiella and E. coli 
bacteremia was 31/122 (23.66 %) with 9 (6.87 %) patients lost to follow up. A similar 
mortality rate was seen in a study done by Paterson et al7 It has been reported that multi 
drug resistant bacteria may result in a much higher mortality among patients with the 
infection.7,36 However we have found a similar mortality rate between patients with 
ESBL and non ESBL producing strains causing bacteremia (25.3% Vs 25.8 %; p= 0.953), 
both the groups having a similar co-morbidity profile. Some studies done before also did 
not show any association between ESBL production and a poor clinical outcome.8  
                      This may be attributed to the fact that approximately half the patients did 
not receive appropriate antibiotic. The initial antibiotic choice was appropriate in only 
43.75% of the patients with bacteremia due to ESBL producing isolates where as 91.42 % 
of the patients with non ESBL producing isolates received an appropriate antibiotic; 
p<0.001. Therefore, our study suggests that ESBL producing bacteria may be associated 
with an increased risk of inappropriate antibiotic treatment due to the multi drug resistant 
characteristics of the pathogen, which in turn, may lead to treatment failure and patient 
death. 
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                   In the study  by Du B et al,8 antibiotic treatment failure was the only 
independent risk factor for hospital mortality (OR 15.376, P=0.001).However, contrary to 
expectations and previous data, our study did not show a worse outcome among patients 
who received inappropriate antibiotic for the episode of bacteremia.. This, again, can be 
attributed to be multi drug resistance among ESBL producing isolates which predominate 
the study isolates, the small sample size and the lack of knowledge of the genotype of the 
isolates.. 
                    It is postulated that the advantage of carbapenems over other antibiotics due 
to their stability against the hydrolytic effects by different β-lactamases including ESBL 
and Amp C may contribute to a better outcome when used as the initial antibiotic of 
choice for the episode of bacteremia . However, we found that the use of a carbapenem as 
the initial antibiotic did not affect the clinical outcome, though in other studies,this had a 
positive effect on outcome.5,7,8 
Clearly, a lot of improvement is still needed in the following fields: 
1. High index of suspicion of gram negative bacteria producing ESBL, especially 
among nosocomially acquired infections. 
2. Judicious use of antibiotics, especially 3rd and 4th generation cephalosporins to 
decrease the chance of bacteria developing resistance 
3. Administration of appropriate empiric antibiotic for each episode of a gram 
negative infection. 
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                                      LIMITATIONS OF THE STUDY 
 
1. Being a tertiary care centre with referral status, the data presented here is not 
likely to be representative of the general population .So while hospital based 
infection control practices may be improved upon based on the recommendations 
presented here, studies looking at regional antimicrobial susceptibility patterns 
will be a more definite step to control the menace of antimicrobial resistance. 
2. Documentations of prior antibiotic administration was suboptimal and this 
reflected on the quality of subset analysis. 
3. Nine patients (6.87%) were lost to follow up 
4. The subset of patients admitted to ICU was small; hence the applicability of the 
SAPS II score as a prognostic tool could not be assessed. Further, the mortality 
and morbidity correlates of this group could not be characterized. 
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                                                         CONCLUSIONS 
 
One hundred and thirty one sequentially encountered adult patients with E coli or 
Klebsiella bacteremia were studied and followed up prospectively over a period of 2 
weeks to assess clinical outcome. 
1. ESBL production was observed in 73.28% of the isolates with 53.06 % of the 
community acquired infection and 85.36% of nosocomial infections caused by ESBL 
producing strains. 
2. Prior use of antibiotics, especially 3rd and 4th generation cephalosporins were 
associated with an increased risk of infection by ESBL producing isolates of E coli 
and Klebsiella 
3. A very high rate (50.4% -81.7%) of resistance to other major classes of antibiotics 
(e.g. fluoroquinolones, aminoglycosides, β-lactams and β-lactamase inhibitors) was 
observed, with carbapenems being the only class of drug with a good activity against 
ESBL producing Enterobacteriaceae. That, resistance to carbapenems was also noted 
among the isolates, is a cause of concern for the future. 
4. Initial antibiotics were inappropriate in 53% (based on antibiotic susceptibility 
profile). 
5. The mortality following the episode of bacteremia was not influenced by the initial 
choice of the antibiotic. However, carbapenems should be the choice of initial empiric 
therapy for serious life threatening infections caused by ESBL producing 
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Enterobacteriaceae (with de-escalation when culture and sensitivity reports are 
available). 
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                                                                    APPENDIX 1      
PITTS s bacteremia score :36,99 
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                                               APPENDIX 2 
SAPS II scoring system :     
       Variables 
      
      
Points 
Unscheduled surgery 8 
Medical 6 
Type of admission 
Scheduled surgery 0 
None 0 
Metastasic Carcinoma 9 
Hematological malignancy 10 
Chronic diseases 
AIDS 17 
<6 26 
6-8 13 
9-10 7 
11-13 5 
Glasgow coma scale 
14-15 0 
<40 0 
40-59 7 
50-59 12 
60-69 15 
70-79 17 
Age 
>80 18 
<70 13 
70-99 5 
100-199 0 
Systolic BP-mm Hg 
>200 2 
<40 11 
40-69 2 
70-119 0 
120-159 4 
Heart Rate 
>160 7 
<39 0 Temperature ºC 
>39 3 
<100 11 
100-199 9 
PaO2 /FiO2 
>200 6 
<500 11 
500-999 4 
Urine output /24 hrs in ml 
>1000 0 
<28 0 
28-83 6 
Serum Urea mg/dL 
 
 >84 10 
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<1000 12 
1000-19000 0 
WBC /mm3 
>19000 3 
<3 3 
3-4.5 0 
Serum Potassium mEq/L 
>4.5 3 
>145 1 
125-144 0 
Serum Sodium mEq/L 
<124 5 
<15 6 
15-19 3 
Serum Bicarbonate mEq/L 
>20 0 
<4 0 
4-5.9 4 
Serum Bilirubin mg/dL 
>6 9 
 
 
SAPS II score calculation; the total score is calculated from the above points for each 
variable. 
The predicted mortality rate is calculated from the following equation 
Logit  = -7,7631+0,0737* (SAPSII) + 0,9971* ln ((SAPSII)+1) 
Predicted Death Rate =e(Logit)/(1+e(Logit)) 
Definitions for SAPS score: 
Age:  Use the patient's age in years at last birthday. 
Heart rate: Use the worst value in 24 hours, either low or high rate; if it varied from 
cardiac arrest (11pts) to extreme tachycardia (7pts), assign 11points. 
SBP: Use the same method as for hearth rate: eg, if it varied from 60 mmHg to 
205mmHg, assign 13 points. 
Body temperature: Use the highest temperature in °C or °F. 
PaO2/FiO2 ratio: If ventilated or CPAP, use the lowest value of the ratio. 
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Urinary output: If the patient is in the intensive care unit for less than 24 hours, make 
the calculation for 24 hours. 
Serum Urea or BUN: Use the highest value in mmol// or g/L for serum urea, in mg/dL 
for the serum urea nitrogen. 
WBC count: Use the worst (high or low) WBC count. 
Serum potassium level: Use the worst (high or low) value. 
Serum Sodium level: Use the worst (high or low) value. 
Serum bicarbonate level: Use the lowest value. 
Bilirubin : Use the highest value in micromol/L or mg/dL. 
Glasgow Coma Score (GCS) : Use the lowest value. If the patient is sedated, record the 
estimated GCS before sedation. 
AIDS: Yes, if HIV positive with clinical complications as Pneumocystis carinii 
pneumonia, Kaposi's sarcoma, Lymphoma, tuberculosis or toxoplasma infection. 
Hematologic malignancy: Yes, if lymphoma, acute leukemia, or multiple myeloma. 
Metastatic cancer: Yes, if proven metastasis by surgery, C.T. scan or any other method. 
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                                                  APPENDIX 3   
PROFORMA  
 
 
Name 
Age :             
Sex :  
Address :                                           
Phone number: 
Hospital No. : 
Ward :       ICU/ non  ICU                            
Department : 
Date of admission : 
Date of isolation of organism :  
Date of discharge:  
Organism grown on culture:  Klebsiella  /  E.coli 
ESBL production  : Yes / No 
Primary diagnosis : 
Co morbidities :   
o diabetes mellitus 
o hypertension 
o chronic liver disease 
o chronic renal failure 
o ischemic heart disease 
o hematological malignancy 
o solid tumor 
o HIV- AIDS 
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Probable source of infection :    
o gastrointestinal  
o genitourinary  
o soft tissue  
o pneumonia  
o CNS infection  
o primary blood stream infection 
o others 
o undetermined 
  
 
 
Prior antibiotic use :  
o Penicillin 
o Cephalosporin 
o Quinolones 
o Aminoglycosides 
o Carbapenems 
o Others   
 
 
 
  
 
 
 
Initial antibiotic used:   
 
o Cefotaxime 
o Ceftazidime 
o Ciprofloxacin 
o Gentamicin 
o Netilmicin 
o Amikacin 
o Piptaz 
o Ticarcillin/Clavulanate 
o Cefoperazone/Sulbactam 
o Imipenem 
o Meropenem 
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Culture sensitivity : 
 
 
 
 
 
 
 
2 week follow up : 
o Alive 
o Dead 
o Lost to follow up 
 
 
 
 
 
                
PITTS score 
 
 
 
 
 
 
SAPS II score 
 
 
       Antibiotic    S    I    R 
  Cefotaxime    
  Ceftazidime    
  Ciprofloxacin    
  Gentamicin    
  Netilmicin    
  Amikacin    
  Piptaz    
  Ticarcillin/Clav    
  Cefoperazone/Sul    
  Imipenem    
  Meropenem    
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                                APPENDIX 4 
  
 
 
                                              INFORMED CONSENT FORM 
 
 
 
 
 
I, Mr / Mrs …………………….,Hosp No…………..   son/daughter/wife of 
Mr………………….. ,  from ......................................,have been explained in detail about 
the proposed study of epidemiology of 2 bacteria ( Escherichia coli and 
Klebsiella)causing blood stream infection. I understand that no intervention will be done 
as part of the study and treatment would depend entirely on the treating physician and 
will not be influenced by the study .I hereby give consent to be part of the proposed 
study, and am willing to be under follow up for 2 weeks. I also understand that I can 
withdraw from the study at any time. 
              
 
 
                                                                              Signature of the patient/relative 
                  
 
                                                                                                 
 
 
Signature of the doctor 
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5. Glossary for master sheet 
 
Dept - Department 
DOD - Date of admission 
DOD - Date of discharge 
DOI - Date of isolation of organism 
Durn - Duration of stay 
Noso/ Com- Nosocomial / community acquired 
HTN - Hypertension 
Solid - Solid tumors 
Hemat - Hamtological Malignancy 
Surgery - Recent surgery 
CLD - Chronic Liver Disease 
DM - Diabetes Mellitus 
IHd - Ischemic Heart Disease 
CRF - Chronic Renal Failure 
Source 
1 - urinary tract 
2- intra abdominal 
3 - undetermined 
 4- pneumonia 
Priorant - Prior antibiotic 
prBeta - Prior beta lactam  
prcef - Prior cephalosporins 
pramin - Prior aminoglycosides 
prquin - Prior Quinolones 
prcarb - Prior carbapenems 
prothers - Prior other antibiotics 
incefo - Initial antibiotic used was Cefotaxime 
incefta - Initial antibiotic used was Ceftazidime 
incefep - Initial antibiotic used was Cefepime 
incefoper - Initial antibiotic used was Cefoperazone - sulbactam 
incipro- Initial antibiotic used was Ciprofloxacin 
inoquin - Initial antibiotic used were quinolones other than Ciprofloxacin 
ingenta- Initial antibiotic used was Gentamicin 
inamin - Initial antibiotic used was Amikacin 
innet - Initial antibiotic used was Netilmicin 
inpip - Initial antibiotic used was Piperacillin - Tazobactam 
intic - Initial antibiotic used was Ticarcillin 
inimi - Initial antibiotic used was Imipenem 
inmero - Initial antibiotic used was  Meropenem 
inaug - Initial antibiotic used was Augmentin 
inothers - Others used as initial therapy 
approp - whether initial antibiotic was appropriate 
ESBL - ESBL production 
Predmort - Predicted mortality 
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Name Hospital NAge Sex Dept DOA DOD DOI DurOrganism Noso/Com Diagnosis HTN Solid
Parimala       446615b 48 female Medicine 07.02.07 21.02.07 08.02.07 15 E coli Nosocomial Urosepsis                     No no
Jegajothi      973142c 60 female Medicine 09.02.07 08.03.07 23.02.07 28 E coli Nosocomial Disseminated malignancy       No Yes
Bakthinathan   512907c 56 male Medicine 15.04.07 05.05.07 15.04.07 21 E coli Nosocomial Urosepsis                     Yes no
Latha          999047c 32 female Medicine 31.03.07 14.04.07 05.04.07 15 E coli Nosocomial Urosepsis with DKA            No no
Arati bhattacha 021528d 64 female Medicine 04.05.07 20.05.07 10.05.07 17 E coli Nosocomial PUO                           No no
Lakshmana      017027d 45 male Medicine 26.04.07 06.06.07 16.05.07 42 E coli Nosocomial Acute Pancreatitis            Yes no
Desai mavi     354269c 48 male Medicine 19.05.07 21.05.07 17.05.07 3 E coli Nosocomial Pleural effusion              Yes no
Nizamudeen     972917c 63 male Hematology 02.02.07 10.03.07 21.02.07 37 E coli Nosocomial AML                           No no
Dipu Malakar   988782c 34 male Hematology 03.04.07 23.04.07 19.04.07 21 E coli Nosocomial AML                           No no
Ganesan        884281c 52 male GEC 25.01.07 15.02.07 06.02.07 22 E coli Nosocomial DCLD-Cryptogenic              No no
Hannah         012841d 49 female other medical 21.04.07 07.05.07 21.04.07 17 E coli Nosocomial Pyelonephritis                No no
Swapna Ghosh  984162c 54 female other medical 12.04.07 05.05.07 22.04.07 24 E coli Nosocomial Diabetic neuropathy           No no
Rama Devi      967463c 44 female Other surgical 24.02.07 03.04.07 28.02.07 39 E coli Nosocomial Mucinous cystadenoma ovary Yes no
Ranjan kumar   970690c 21 male Hematology 30.01.07 21.02.07 04.02.07 22 Klebsiella Nosocomial Pre B ALL                     No no
Subramaniam    030681d 60 male Hematology 22.05.06 01.06.07 27.05.06 11 Klebsiella Nosocomial ALL                           No no
Taharur        025799d 27 female other medical 17.05.07 11.06.07 30.05.07 26 Klebsiella Nosocomial TEN                           No no
Shyam Sundar   974900c 51 male Other surgical 25.04.07 11.05.07 01.05.07 17 Klebsiella Nosocomial Voluntary Kidney donor        No no
Venugopal      965733c 48 male Other surgical 27.01.07 08.02.07 03.02.07 13 Klebsiella Nosocomial RTA                           No no
Siba Shankar   997294c 69 male ICU 23.03.07 31.05.07 13.05.07 70 Klebsiella Nosocomial PPI Endocarditis              No no
Loganathan     993167c 46 male Medicine 19.03.07 09.04.07 19.03.07 22 E coli Community Rt Pyelonephritis             No no
Gnanamani      985754c 34 female Medicine 23.03.07 25.03.07 24.03.07 3 E coli Community Pyelonephritis                No no
Palani         029842d 37 male Other surgical 26.05.07 27.05.07 24.05.07 2 E coli Community Pyelonephritis                No no
Narayana chowd896143c 60 male Medicine 15.02.07 30.03.07 16.03.07 44 E coli Nosocomial Craniopharyngioma             Yes Yes
Krishna        884539c 28 male Medicine 04.04.07 26.04.07 10.04.07 23 E coli Nosocomial Sepsis                        No no
Srinivasulu    808349c 76 male Surgery 24.04.07 07.05.07 02.05.07 14 E coli Nosocomial laproscopic Cholecystectomy  No no
Rajan          430288c 40 male Hematology 13.04.07 03.05.07 03.05.07 21 E coli Nosocomial Aplastic anemia               No no
Pushpa Giri    963898c 41 male Hematology 19.01.07 13.03.07 01.03.07 53 E coli Nosocomial AML                           No no
Rajat          981651c 27 male Hematology 04.05.07 31.05.07 19.05.07 28 E coli Nosocomial ALL                           No no
Chandrasekhar  025503d 62 male Other surgical 11.05.07 17.05.07 11.05.07 7 E coli Nosocomial Pyelonephritis                Yes no
Manoj Kumar    970366c 22 male Other surgical 10.03.07 30.03.07 27.03.07 21 E coli Nosocomial Ameloblastoma                 No no
Ponkodi        013460d 23 female Medicine 26.04.07 11.05.07 11.05.07 16 Klebsiella Nosocomial DKA                           No no
Alphy Kurien   942535c 21 male Hematology 23.01.07 13.04.07 03.03.07 81 Klebsiella Nosocomial pre B ALL                     No no
Tafsil Begum   902665c 30 female Hematology 05.02.07 30.04.07 22.03.07 85 Klebsiella Nosocomial AML                           No no
Ramalingam     957367c 76 male Medicine 23.04.07 08.05.07 23.04.07 16 E coli Community Urosepsis                     No no
Srinivasulu    018385d 51 male Medicine 04.05.07 07.05.07 04.05.07 4 E coli Community Urosepsis                     No no
Victoria       896462 38 female Surgery 29.04.07 16.05.07 30.04.07 18 E coli Community Pyelonephritis                No no
Ponnuswamy     463128c 65 male Hematology 30.04.07 01.05.07 30.04.07 2 E coli Community Multiple Myeloma              Yes no
Labubala       988622c 55 female Other surgical 30.03.07 11.04.07 30.03.07 13 E coli Nosocomial CABG post op                  No no
Mirunalini     988205c 52 female ICU 09.03.07 25.03.07 11.03.07 17 E coli Nosocomial PUO                           No no
Rajendran      978708c 55 male ICU 31.03.07 09.04.07 01.04.07 10 E coli Nosocomial Cellulitis Rt Gluteal region  No no
Tarun Bhowmik 989790c 45 male Surgery 13.05.07 08.06.07 21.05.07 27 Klebsiella Nosocomial Familial adenomatous polyposNo no
Khadar         967925c 66 male Hematology 05.02.07 23.02.07 13.02.07 19 Klebsiella Nosocomial Aplastic anemia               No no
Murthy         990073c 46 male Medicine 10.03.07 21.03.07 11.03.07 22 E coli Nosocomial Urosepsis                     No no
Kodandan       035024d 75 male Medicine 28.05.07 08.06.07 28.05.07 2 E coli Nosocomial Urosepsis                     No no
Hillarius      953800c 65 male Surgery 12.02.07 06.03.07 18.02.07 23 E coli Nosocomial Periampullary carcinoma       Yes Yes
Rajeswari      977168c 50 female Hematology 16.02.07 28.04.07 27.02.07 72 E coli Nosocomial AML                           No no
Mohammed Nas982892c 49 male GEC 15.03.07 09.04.07 30.03.07 25 E coli Nosocomial DCLD -HCV related,HCC        No Yes
Shankari Shili 734648c 31 female other medical 14.04.07 18.04.07 17.04.07 5 E coli Nosocomial Nephrotic syndrome            Yes no
Sivaraj        013922d 51 male other medical 21.04.07 07.05.07 24.04.07 17 E coli Nosocomial NSTEMI                        Yes no
Badal maity    980035c 51 male other medical 27.02.07 08.03.07 28.02.07 10 E coli Nosocomial Urosepsis                     No no
Suraiya        705095c 58 female other medical 16.05.07 05.06.07 30.05.07 21 E coli Nosocomial CKD                           Yes no
Thanigavathy   997937c 26 female Other surgical 30.03.07 03.04.07 31.03.07 5 E coli Nosocomial Postpartum                    No no
Sandhya Shaw  587451c 45 female GEC 16.04.07 01.06.07 17.05.07 47 Klebsiella Nosocomial PUO                           No no
Surendra       999010c 47 male ICU 27.03.07 19.04.07 01.04.07 24 Klebsiella Nosocomial RTA                           No no
Dhakshinamurth 880731c 63 male Medicine 22.03.07 30.03.07 21.03.07 9 E coli Community Urosepsis                     No no
Krishnamurthy  959021c 78 male Medicine 06.02.07 20.02.07 06.02.07 15 E coli Community Urosepsis                     No no
Kesavan        919636c 76 male Medicine 30.03.07 16.04.07 31.03.07 18 E coli Community Urosepsis                     Yes no
Ravi E         999428c 46 male Medicine 06.04.07 20.04.07 06.04.07 15 E coli Community DKA                           No no
Salammal       339662c 63 female Medicine 01.05.07 02.05.07 02.05.07 2 E coli Community Urosepsis                     Yes no
Deivanai       971476c 75 female Medicine 12.02.07 12.02.07 12.02.07 1 E coli Community Urosepsis                     No no
Mary Philip    051571c 82 female Medicine 18.04.07 19.04.07 19.04.07 2 E coli Community LRI                           No no
Manoj Biswas   013790d 39 male GEC 08.05.07 14.05.07 08.05.07 7 E coli Community DCLD -HCV related             No no
Murugamma      006611d 54 female Other surgical 10.04.07 19.04.07 10.04.07 10 E coli Community Pyelonephritis emphysematou No no
Ponkodi        013460d 23 female ICU 28.04.07 11.05.07 25.04.07 14 E coli Community Urosepsis                     No no
Kanniappan     758289a 71 male Medicine 29.03.07 30.03.07 29.03.07 2 Klebsiella Community Bronchiectasis                Yes no
Shanmugavel    002344d 64 male GEC 30.03.07 02.04.07 30.03.07 4 Klebsiella Community Fulminant hepatitis E         No no
Periyasamy     965958c 40 male Medicine 01.02.07 20.02.07 01.02.07 20 E coli Nosocomial Urosepsis                     No no
Sampoornam     030561d 54 female Medicine 25.05.06 07.06.07 25.05.06 14 E coli Nosocomial Urosepsis                     No no
Thiruvanakarasu025544d 39 male Medicine 12.05.07 21.05.07 18.05.07 10 E coli Nosocomial Aseptic Meningitis            No no
Sethuraman     993224c 26 male Medicine 20.03.07 10.04.07 30.03.07 22 E coli Nosocomial OP poisoning                  No no
Soundari       972817c 20 female Surgery 04.02.07 15.02.07 04.02.07 12 E coli Nosocomial TB ileal perforation          No no
Ravanth Kumar 023646d 20 male Surgery 10.05.07 19.05.07 13.05.07 10 E coli Nosocomial RTA                           No no
Jain D         027237d 54 male Surgery 15.05.07 21.05.07 19.05.07 7 E coli Nosocomial Cheledocholithiasis           No no
Krishnan       993401c 55 male Surgery 25.03.07 08.04.07 26.03.07 15 E coli Nosocomial Necrotising fasciitis Lt LL   No no
Varghese       960895c 70 male Hematology 22.02.07 14.03.07 02.03.07 21 E coli Nosocomial B cell Lymphoma               Yes Yes
Hajee Md       726044c 54 male Hematology 03.04.07 16.04.07 15.04.07 14 E coli Nosocomial Metastatic neuroendocrine tumNo Yes
Ramesh Chandr 988823c 60 male GEC 08.03.07 14.03.07 09.03.07 7 E coli Nosocomial DCLD-HBV related              No no
Narmada        991457c 59 female other medical 22.04.07 09.05.07 22.04.07 18 E coli Nosocomial Bronchogenic carcinoma        No Yes
Rev Paul Thoma215605c 66 male other medical 22.01.07 10.04.07 11.03.07 79 E coli Nosocomial Demyelinating disease         Yes no
Saravanan      013422d 26 male other medical 28.04.07 07.05.07 29.04.07 11 E coli Nosocomial Pyelonephritis                No no
Shameen        970470c 41 female Other surgical 29.01.07 10.02.07 05.02.07 13 E coli Nosocomial Post partum Febrile illness   Yes no
Chinnakilli    908241c 63 female Other surgical 17.05.07 10.06.07 19.05.07 25 E coli Nosocomial CABG post op                  Yes no
Naganathan     965860c 84 male Surgery 30.01.07 03.02.07 01.02.07 5 Klebsiella Nosocomial Obstr periumbilical hernia    No no
Rita Rani      210983c 49 female Surgery 12.01.07 21.04.07 13.02.07 ## Klebsiella Nosocomial Ulcerative colitis            No no
Bhupathy       019208d 30 male Hematology 29.04.07 06.05.07 05.05.07 8 Klebsiella Nosocomial AML                           No no
Rama Kanta Jan936554c 51 male other medical 06.02.07 09.04.07 23.03.07 63 Klebsiella Nosocomial ADPKD                         Yes no
Jayakumar      753923c 36 male ICU 07.05.07 08.05.07 06.05.07 2 Klebsiella Nosocomial Acute Pancreatitis            No no
Fathima        641040b 59 female ICU 23.03.07 08.04.07 23.03.07 14 Klebsiella Nosocomial Aspiration pneumonia          Yes no
Sekar          006839d 45 male Medicine 13.04.07 02.05.07 14.04.07 20 E coli Community Urosepsis                     No no
Kanchana       287037a 67 female Medicine 17.04.07 03.05.07 17.04.07 17 E coli Community Urosepsis                     Yes no
Anjali Saha    014040d 50 female Surgery 25.04.07 07.05.07 25.04.07 13 E coli Community Cholangitis                   No no
Mahadevan      013853a 50 male other medical 11.05.07 13.05.07 12.05.07 4 E coli Community Lupus nephritis               No no
Thavamani      993255c 45 female Surgery 27.04.07 30.04.07 27.04.07 4 E coli Nosocomial Urosepsis                     No no
Varalaxmi      013202d 20 female Medicine 22.04.07 04.05.07 23.04.07 13 E coli Community Urosepsis                     No no
Shenbagaraj    968704c 53 male GEC 14.02.07 19.02.07 14.02.07 6 E coli Community CLD                           No no
Pradeep Peter  986326c 23 male GEC 18.04.07 20.04.07 19.04.07 3 E coli Community DCLD                          No no
Salamma        988269c 49 female Medicine 11.03.07 17.03.07 13.03.07 7 E coli Nosocomial Cerebrovascular accident      Yes no
Vijaya Kennedy 783309c 38 female Hematology 17.03.07 19.04.07 30.03.07 33 E coli Nosocomial CML                           No no
Washington     383868b 51 male GEC 20.04.07 01.05.07 24.04.07 12 Klebsiella Nosocomial DCLD- Ethanol related         No no
Jothi          114676c 70 female Medicine 19.03.07 31.03.07 20.03.07 13 E coli Community Cerebrovascular accident      Yes no
Rugmani        432911b 55 female Medicine 30.04.07 05.05.07 30.04.07 6 E coli Community Pyelonephritis                No no
Valliyammal    685782c 73 female Medicine 07.05.07 09.05.07 07.05.07 3 E coli Community Urosepsis                     Yes no
Vadivambal     975700c 64 female Medicine 16.02.07 22.02.07 16.02.07 7 E coli Community Acute coronary syn            Yes no
Balaji         029999d 25 male GEC 28.05.07 05.06.07 28.05.07 9 E coli Community Wilsons disease               No no
Logaranjan     744329c 37 male GEC 10.05.07 16.05.07 11.05.07 7 E coli Community DCLD -Ethanol related         No no
Sheik Nawab    013204d 39 male GEC 22.04.07 23.04.07 23.04.07 2 E coli Community Subacute hepatic failure      No no
Rajamma        671792c 70 female other medical 25.03.07 29.03.07 25.03.07 5 E coli Community Urosepsis                     Yes no
Saroja         324268b 68 female other medical 25.05.07 29.05.07 26.05.07 5 E coli Community Pyelonephritis                Yes no
Devaraj        029784d 37 male ICU 22.05.07 03.06.07 22.05.07 13 E coli Community CLD - Alcohol related         No no
Purnima Ghosh 027584d 39 female GEC 17.05.07 22.05.07 16.05.07 6 Klebsiella Community Cholangitis                   No no
Thakur         008003d 50 male ICU 10.04.07 12.04.07 10.04.07 3 Klebsiella Community Exudative pericarditis        No no
Rabindra       001593d 47 male GEC 14.04.07 18.04.07 16.04.07 5 E coli Nosocomial DCLD                          No no
Toshi Ao       003069d 35 male GEC 04.04.07 15.04.07 12.04.07 12 E coli Nosocomial Disseminated malignancy       No Yes
Sandha         933942c 58 female other medical 09.02.07 12.02.07 08.02.07 4 E coli Nosocomial Carcinoma Cervix              No no
Sabtri Shaw    992797c 42 female Surgery 07.05.07 22.05.07 14.05.07 16 Klebsiella Nosocomial Carcinoma head of pancreas  No Yes
Devakumari     975777c 48 female Medicine 28.02.07 03.03.07 28.02.07 4 E coli Community Urosepsis                     No no
Kamala bai     486808a 89 female Medicine 23.03.07 09.04.07 24.03.07 15 E coli Community Urosepsis                     Yes no
Thirumala reddy 993038c 60 male Medicine 15.03.07 28.03.07 15.03.07 14 E coli Community Sepsis                        No no
Gopuram Ravi   986527c 39 male Medicine 28.02.07 12.03.07 01.03.07 13 E coli Community Chronic pancreatitis          No no
Adeline Priya  641312c 23 female Hematology 30.03.07 16.04.07 30.03.07 18 E coli Community AML                           No no
Sahajada Md    336481c 30 male Hematology 18.03.07 18.03.07 18.03.07 1 E coli Community Aplastic anemia               No no
Bhaskar        704754c 46 male GEC 12.03.07 11.04.07 12.03.07 31 E coli Community CLD -Ethanol related          No no
Rubini         937919c 22 female Other surgical 06.04.07 14.04.07 06.04.07 9 E coli Community Postpartum urosepsis          No no
Dhanuram       972816c 57 male ICU 02.02.07 10.02.07 05.02.07 9 E coli Nosocomial CRF                           No no
Prakash        948090b 33 male Hematology 05.05.07 06.06.07 14.05.07 33 Klebsiella Nosocomial CML                           No no
Vijayalakshmi  801826c 33 female other medical 20.05.07 21.05.07 01.05.07 2 E coli Community Renal allograft recipient     No no
Nagaraju       910556c 23 male Hematology 04.02.07 13.02.07 04.02.07 10 E coli Community AML                           No no
Thangavel      006698d 68 male Hematology 13.04.07 04.05.07 13.04.07 22 Klebsiella Community B cell Lymphoma               No no
Kananath       963069c 45 male Surgery 19.03.07 02.04.07 31.03.07 14 Klebsiella Nosocomial Periampullary carcinoma       No Yes
Rani Selvaraj  642219a 38 female Surgery 17.02.07 05.05.07 19.04.07 78 Klebsiella Nosocomial Chronic pancreatitis          No no
Chitra         971462c 43 female other medical 05.03.07 13.03.07 06.03.07 9 E coli Nosocomial Renal Calculus                No no
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Yes No No No No No No No Yes No yes Sensitive Sensitive Resistant Sensitive Sensitive
No Yes No No No No Yes No No Yes yes Sensitive Sensitive Sensitive Sensitive Sensitive
No Yes No No No No No No No No yes Sensitive Sensitive Sensitive Sensitive Sensitive
No No No No No No No No No No no Sensitive Sensitive Sensitive Sensitive Sensitive
No No No No No No No No No No no Sensitive Sensitive Sensitive Sensitive Sensitive
No No No No No No No No No Yes no Sensitive Sensitive Sensitive Sensitive Sensitive
Amikacin Piptaz Ticarcillin Cefoperaz Imipenem Meropenem ESBL PITT's SAPSII Predmort Outcome
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 0 . . Alive
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 0 . . Alive
Resistant Resistant Resistant Sensitive Sensitive Sensitive yes 1 . . Alive
Resistant Intermediate Resistant Intermediate Sensitive Sensitive yes 1 . . Dead
Resistant Resistant Resistant Intermediate Sensitive Sensitive yes 0 . . Alive
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 2 . . Alive
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 2 . . Dead
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 0 . . Alive
Sensitive Sensitive Intermediate Intermediate Sensitive Sensitive yes 0 . . Dead
Sensitive Intermediate Resistant Resistant Sensitive Sensitive yes 0 . . Alive
Sensitive Resistant Resistant Intermediate Sensitive Sensitive yes 0 . . Alive
Sensitive Resistant Resistant Sensitive Sensitive Sensitive yes 0 . . Alive
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 0 . . Alive
Resistant Resistant Resistant Intermediate Sensitive Sensitive yes 0 . . Alive
Resistant Resistant Resistant Intermediate Sensitive Sensitive yes 0 . . Lost to follow up
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 0 . . Alive
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 2 . . Alive
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 0 . . Alive
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 4 21 4.2 Alive
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 3 . . Alive
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 2 . . Alive
Sensitive Resistant Resistant Intermediate Sensitive Sensitive yes 1 . . Alive
Resistant Resistant Resistant Intermediate Sensitive Sensitive yes 0 . . Alive
Resistant Sensitive Resistant Sensitive Sensitive Sensitive yes 1 . . Alive
Resistant Resistant Resistant Sensitive Sensitive Sensitive yes 1 . . Lost to follow up
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 10 . . Dead
Resistant Resistant Resistant Intermediate Sensitive Sensitive yes 1 . . Alive
Sensitive Intermediate Intermediate Intermediate Sensitive Sensitive yes 0 . . Alive
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 1 . . Alive
Resistant Resistant Resistant Intermediate Sensitive Sensitive yes 2 . . Alive
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 11 . . Dead
Resistant Resistant Resistant Intermediate Sensitive Sensitive yes 0 . . Alive
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 0 . . Alive
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 1 . . Alive
Sensitive Resistant Resistant Resistant Sensitive Sensitive yes 4 . . Alive
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 0 . . Alive
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 3 . . Dead
Resistant Resistant Resistant Intermediate Sensitive Sensitive yes 0 . . Alive
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 5 58 64 Dead
Sensitive Intermediate Resistant Sensitive Sensitive Sensitive yes 6 62 71.9 Dead
Sensitive Resistant Resistant Intermediate Sensitive Sensitive yes 0 . . Alive
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 1 . . Alive
Resistant Resistant Resistant Intermediate Sensitive Sensitive yes 0 . . Alive
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 0 . . Alive
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 1 . . Alive
Sensitive Resistant Resistant Intermediate Sensitive Sensitive yes 0 . . Alive
Sensitive Resistant Resistant Resistant Sensitive Sensitive yes 0 . . Alive
Resistant Intermediate Resistant Resistant Sensitive Sensitive yes 0 . . Alive
Resistant Resistant Resistant Intermediate Sensitive Sensitive yes 1 . . Alive
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 0 . . Alive
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 0 . . Alive
Resistant Resistant Resistant Sensitive Sensitive Sensitive yes 1 . . Lost to follow up
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 0 . . Alive
Resistant Intermediate Resistant Intermediate Sensitive Sensitive yes 4 55 57.5 Alive
Sensitive Resistant Resistant Intermediate Sensitive Sensitive yes 1 . . Alive
Sensitive Resistant Resistant Intermediate Sensitive Sensitive yes 1 . . Alive
Resistant Intermediate Resistant Sensitive Sensitive Sensitive yes 0 . . Alive
Resistant Resistant Resistant Intermediate Sensitive Sensitive yes 0 . . Alive
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 9 . . Dead
Resistant Sensitive Resistant Intermediate Sensitive Sensitive yes 3 . . Dead
Sensitive Sensitive Intermediate Intermediate Sensitive Sensitive yes 6 . . Dead
Sensitive Sensitive Resistant Resistant Sensitive Sensitive yes 0 . . Alive
Sensitive Sensitive Resistant Sensitive Sensitive Sensitive yes 1 . . Alive
Sensitive Sensitive Resistant Intermediate Sensitive Sensitive yes 5 59 66.1 Alive
Sensitive Resistant Resistant Intermediate Sensitive Sensitive yes 6 . . Dead
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 4 . . Dead
Resistant Resistant Resistant Intermediate Sensitive Sensitive yes 0 . . Alive
Sensitive Resistant Resistant Intermediate Sensitive Sensitive yes 0 . . Alive
Sensitive Intermediate Resistant Intermediate Sensitive Sensitive yes 0 . . Dead
Resistant Resistant Resistant Intermediate Sensitive Sensitive yes 1 . . Alive
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 0 . . Alive
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 0 . . Alive
Resistant Resistant Resistant Intermediate Sensitive Sensitive yes 1 . . Alive
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 1 . . Alive
Resistant Resistant Intermediate Sensitive Sensitive Sensitive yes 1 . . Alive
Resistant Resistant Resistant Sensitive Sensitive Sensitive yes 7 . . Dead
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 0 . . Lost to follow up
Resistant Resistant Resistant Intermediate Sensitive Sensitive yes 1 . . Alive
Resistant Resistant Resistant Resistant IntermediatResistant yes 1 . . Alive
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 1 . . Alive
Resistant Resistant Resistant Intermediate Sensitive Sensitive yes 1 . . Lost to follow up
Resistant Resistant Resistant Intermediate Sensitive Sensitive yes 2 . . Alive
Resistant Resistant Resistant Intermediate Sensitive Sensitive yes 3 . . Dead
Resistant Resistant Resistant Intermediate Sensitive Sensitive yes 1 . . Alive
Sensitive Resistant Resistant Intermediate Sensitive Sensitive yes 9 . . Dead
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 3 . . Alive
Sensitive Resistant Resistant Resistant Sensitive Sensitive yes 4 . . Dead
Resistant Resistant Resistant Resistant Sensitive Sensitive yes 3 25 6.5 Alive
Sensitive Resistant Resistant Sensitive Sensitive Sensitive yes 0 . . Alive
Resistant Resistant Resistant Intermediate Sensitive Sensitive yes 0 . . Alive
Sensitive Resistant Resistant Resistant Sensitive Sensitive yes 2 . . Dead
Sensitive Intermediate Resistant Intermediate Sensitive Sensitive yes 10 . . Dead
Sensitive Resistant Resistant Resistant Sensitive Sensitive yes 1 . . Dead
Sensitive Intermediate Resistant Sensitive Sensitive Sensitive yes 3 . . Alive
Sensitive Intermediate Resistant Resistant Sensitive Sensitive yes 4 . . Dead
Sensitive Resistant Resistant Intermediate Sensitive Sensitive yes 8 . . Dead
Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive No 0 . . Dead
Sensitive Intermediate Sensitive Sensitive Sensitive Sensitive No 3 . . Alive
Sensitive Resistant Sensitive Intermediate Sensitive Sensitive No 0 . . Lost to follow up
Sensitive Intermediate Sensitive Sensitive Sensitive Sensitive No 2 . . Alive
Sensitive Sensitive Resistant Sensitive Sensitive Sensitive No 1 . . Alive
Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive No 0 . . Lost to follow up
Sensitive Sensitive Resistant Sensitive Sensitive Sensitive No 0 . . Alive
Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive No 0 . . Alive
Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive No 0 . . Alive
Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive No 8 . . Dead
Sensitive Intermediate Intermediate Intermediate Sensitive Sensitive No 0 . . Alive
Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive No 0 . . Alive
Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive No 1 34 15.3 Dead
Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive No 0 . . Alive
Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive No 10 54 55.3 Dead
Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive No 2 . . Dead
Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive No 0 . . Lost to follow up
Sensitive Sensitive Intermediate Sensitive Sensitive Sensitive No 1 . . Dead
Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive No 0 . . Alive
Sensitive Intermediate Resistant Intermediate Sensitive Sensitive No 0 . . Alive
Sensitive Sensitive Resistant Intermediate Sensitive Sensitive No 1 . . Alive
Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive No 1 . . Alive
Sensitive Sensitive Resistant Sensitive Sensitive Sensitive No 1 . . Alive
Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive No 3 . . Alive
Sensitive Sensitive Resistant Sensitive Sensitive Sensitive No 8 . . Dead
Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive No 1 . . Alive
Sensitive Sensitive Resistant Sensitive Sensitive Sensitive No 0 . . Alive
Resistant Resistant Resistant Sensitive Sensitive Sensitive No 5 . . Dead
Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive No 0 . . Alive
Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive No 0 . . Alive
Sensitive Resistant Sensitive Sensitive Sensitive Sensitive No 0 . . Alive
Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive No 0 . . Alive
Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive No 0 . . Lost to follow up
Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive No 0 . . Alive
Sensitive Sensitive Resistant Sensitive Sensitive Sensitive No 0 . . Alive
